Molecular reorganization of endocannabinoid signalling in Alzheimer's disease by Mulder, Jan et al.
For Peer Review
 
 
 
 
 
 
 
Molecular reorganization of endocannabinoid signalling in 
Alzheimer's disease 
 
 
Journal: Brain 
Manuscript ID: BRAIN-2010-01821.R1 
Manuscript Type: Original Paper 
Date Submitted by the 
Author: 
n/a 
Complete List of Authors: Mulder, Jan; University of Aberdeen, ENI-Aberdeen 
Zilberter, Misha; Karolinska Institutet, Medical Biochemistry & 
Biophysics 
Pasquare, Susana; Cajal Institute, Department of Cellular, 
Molecular and Developmental Neuroscience 
Alpar, Alan; University of Aberdeen, ENI-Aberdeen 
Schulte, Gunnar; Karolinska Institutet, Pharmacology & Physiology 
Ferreira, Samira; University of Coimbra 
Köfalvi, Attila; University of Coimbra 
Martin Moreno, Ana; Cajal Institute, Department of Cellular, 
Molecular and Developmental Neuroscience 
Keimpema, Erik; University of Aberdeen, ENI-Aberdeen 
Tanila, Heikki; University of Eastern Finland, A.I. Virtanen Institute 
Watanabe, Masahiko; Hokkaido University School of Medicine, 
Department of Anatomy 
Mackie, Ken; Indiana University, Gill Center for Neuroscience 
Hortobagyi, Tibor; King's College London, Institute of Psychiatry 
de Ceballos, María; Cajal Institute, Department of Cellular, 
Molecular and Developmental Neuroscience 
Harkany, Tibor; Karolinska Institutet, Medical Biochemistry & 
Biophysics; University of Aberdeen, ENI-Aberdeen 
Key Words:   
Please choose up to 5 
keywords from the list: 
cannabinoids, Alzheimers disease, synapse function, cerebral 
cortex, Neuronal Plasticity 
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
  
 
 
 
Page 1 of 70
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
    
 Page: 3 / 10 
 
 
Specific responses to Referee 1: 
 
Thank you for your supportive comments, useful criticism and balanced view on our manuscript. We 
were glad to learn that you find our manuscript significant. We have dealt with each of your queries in 
detail. Please find our specific responses to your criticism below. 
 
Q1: ‘1. Fig. 1A: The data appear to show a profound reduction in SNAP25 and PSD95, common synaptic 
proteins, in AD preparations compared to control. Does this reflect a decrease in synaptic numbers? If so, 
this might contribute to synaptic transmission deficiency irrespective of 2-AG signalling. Other 
conclusions which the authors base on a difference in immunostaining might also be affected by this 
general trend.’ 
 
Synaptic dysfunction is a key pathogenic component of Alzheimer’s disease. It is generally accepted that 
excitatory synapses may be preferentially targeted by beta-amyloid (Aβ). Therefore, it is relevant to 
assess synaptic protein concentrations (Fig. 1A, Supporting Fig. 1). Endocannabinoids can affect both 
excitatory and inhibitory neurotransmission through CB1 cannabinoid receptors (CB1Rs). Indeed, 
disease-related deficiency of synaptic neurotransmission may impact endocannabinoid signalling that is, 
in our view, one key neuromodulatory homeostatic system to define the dynamics of presynaptic 
neurotransmitter release. 
 
• To address the mechanistic scenario you have outlined we have introduced an additional 
paragraph in our discussion (page 17, text in blue). 
• Is the loss of CB1R-mediated 2-AG signalling a simple reflection of synapse elimination? We think 
not given the lack of a relationship between CB1R and presynaptic protein (SNAP25) 
concentrations in Alzheimer’s brains. Similarly, a lack of PSD95/DAGL relationship (in the 
postsynapse) suggests that modifications to 2-AG synthesis in AD are, at least in part, 
independent from synapse loss. 
• Our manuscript aims to describe changes to the molecular control of 2-AG availability and signal 
competence. We, in the present report, did not address the synapse specificity of 2-AG 
dysfunction. Is this question of overall importance? We stand firm in our view that, in a primary 
research report, it is not. We nevertheless believe that follow-up studies may uncover 
interesting contributions of e.g., specific basket cell subtypes or pyramidal cell subsets to 
regulating particular aspects of endocannabinoid signalling in AD. 
• During studying DSI, we have considered endocannabinoid signalling as a subsystem which may 
play a modulatory role in synaptic processing. We used acute Aβ superfusion (60 min). This brief 
synaptotoxic insult is unlikely to (physically) eliminate synapses from the hippocampal networks 
we have studied. Therefore, our conclusions that Aβ instead disrupts the timing of DSI are 
warranted. Since perisomatic DSI is largely induced at a homogenous population of GABAergic 
terminals (originating from cholecystokinin-positive basket cells), we believe that the apparent 
change in DSI decay will reflect the response of this specific terminal subset. We have stated this 
on page 17 of the revised manuscript. 
 
Q2: ‘2. Fig. 1E: The text mentions "strong inverse relationship between DAGalpha and DAGbeta levels". 
This is however not what the data scatter suggests.’ 
 
Fig. 1E (revised Fig. 1D) examines the expressional relationship between DAGLalpha and DAGLbeta. 
 
• There is no correlation between the levels of these two enzymes when sampling the overall 
subject cohort. 
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• However, a negative correlation is evident when specifically sampling the Braak 6 cohort. 
• We have clarified the expressional relationship existing in severe Alzheimer’s by specifically 
retaining the regression line for the Braak 6 group (in red). 
 
Q3: ‘Colocalisation studies based on fluorescence imaging are notoriously prone to spurious correlation. 
Because conclusions of the present manuscript rely heavily on such data it would be important to 
understand the error involved. The authors should attempt to assess spatial resolution of the methods 
involved, which is unlikely to be better than 0.5-0.7 micron in the z-direction.  Further detail should be 
provided with respect to the 3-D reconstruction and surface rending approaches used. Ideally, control 
samples with non-specific staining obtained in similar conditions should be used to gauge the spurious 
correlations involved. Seeing a difference between healthy and AD preparations deals with this issue 
only to some extent.’ 
 
We agree with your view that assessment of the reliability of the imaging techniques we used requires 
detailed description of the methods involved and presenting control data. In the original submission, we 
have only provided a succinct passage on the imaging tools used given that we have provided a 
relatively detailed descripti n of these recently, including spectral image controls (Halleskog et al., Glia 
(2011) 59;119-131). 
 
• Since we rely on laser-scanning microscopy analysis, the spatial resolution (in z direction) will not 
be better than 500-700 nm (considering Abbe’s diffraction limit and the NA of our objectives). 
But, we have imaged structures in the micrometer range throughout and therefore do not think 
that these obvious physical limits will affect the quality of our data. We have specified the x/y/z 
resolution scale used during three-dimensional on page 4 of the Supplementary Information. 
 
We also have: 
• provided spectral analysis of the specificity of each fluorochrome (Supplementary Fig. 3), 
• compared the various background quenching, antigen retrieval and staining protocols 
(Supplementary Fig. 3) to control for non-specific background, 
• described in detail the imaging and reconstruction protocols we have used (pages 3-4 (text in 
blue) of the Supplementary Methods), 
• homogenized fluorescence excitation of fluorochromes from different specimens 
(Supplementary Fig. 6) to minimize bias in our quantitative profiling. Please note that the 
extensive revisions have, in some instances, affected the total (%) values of e.g., area coverage. 
However, none of the modifications we introduced affected the ratio of co-localization of select 
marker combinations. Our conclusions are warranted since we use this latter parameter 
throughout the study as decisive read-out. 
• edited the manuscript text accordingly. 
 
Q4: ’Fig. 8B: Because this is the only physiological experiment lending support to the main hypothesis it 
would be important to understand its details. The AM281 control data need to be shown, either here or 
in the Supplementary. Because TTX is not mentioned, one assumes that the recorded spontaneous 
activity is action potential dependent. If so the observed changes may reflect network activity rather 
than changes in synaptic transmission per se. In general, extending physiological tests would greatly 
improve the manuscript.’ 
 
Thank you for raising these important points. We have: 
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• included data on AM251 effects: AM251-induced inhibition of DSI under control conditions has 
previously been shown in many publications. Therefore, we present only the summary diagram 
in Fig. 8C. In turn, we show an example experiment in Supplementary Fig. 10. 
• We have performed another series of important control experiments to exclude that the Aβ-
induced enhancement of DSI is due to the release of a non-endocannabinoid retrograde 
messenger. We show (Fig. 8D,D1) that AM251 eliminates DSI even upon Aβ exposure. 
• TTX was not present in ACSF during the DSI recordings, and accordingly, the recorded activity is 
referred to as “spontaneous IPSCs (sIPSC)”, rather than “miniature IPSCs (mIPSC)”, which would 
be the case in action potential-independent, quantal neurotransmission. However, our DSI 
recordings were done under a blockade of both AMPA and NMDA channels (by applying CNQX 
and APV throughout the duration of the experiment), and thus in the absence of excitatory 
neurotransmission. As the recorded postsynaptic cell, a CA1 pyramidal neuron is itself 
glutamatergic, it is reasonable to conclude that the observed Aβ-induced changes in DSI kinetics 
are not network-related. 
 
Q5: ‘Because CB1 receptors are thought to affect predominantly inhibitory transmission the 
enhancement in cannabinoid signalling attributed to AD may actually result in enhanced excitatory 
activity in the brain.  This general issue has to be dealt with.’ 
 
This is a very important point, which we did not specifically address in the original manuscript: mainly, 
what, if any, changes does Aβ induce in 2AG-mediated modulation of excitatory neurotransmission? It 
has been reported that glutamatergic neurons in hippocampus also exhibit depolarization-induced 
suppression of excitation (DSE), which is mediated by endocannabinoids (reviewed by Kano et al. 
Physiol Rev (2009) 89: 308-380). It is possible that the release of endocannabinoids from the 
postsynaptic cell has a double effect, in suppressing both its inhibitory and excitatory inputs. In relation 
to neuronal excitability, then, what is the total effect of such endocannabinoid release, and what are 
the changes brought about by Aβ? 
 
• We have performed additional experiments in an attempt to address these questions. 
 
• Previous studies on DSE have recorded both spontaneous and evoked excitatory currents 
(EPSCs) under the blockade of GABAA receptors. We feel, however, that such an approach 
introduces a variable that, while influencing the outcome, is impossible to compensate for. 
Namely, it is accepted that under a total GABAA receptor blockade (whether by picrotoxin or 
bicuculline), the neuronal network becomes highly hyperactive, even epileptic. The hyperactivity 
is not constant, but dynamic, with periods of high activity followed by quiescent periods. Thus, 
recording any long-term changes of EPSC amplitudes under an unpredictable factor of an 
epileptic network activity is – in our opinion – highly unreliable. 
We have attempted, therefore, to elucidate the possible effect of Aβ on endocannabinoid 
modulation of excitatory neurotransmission using alternative means. Namely, Hajos & Freund 
have reported that the application of WIN55,212-2, a CB1R/CB2R agonist, significantly reduces 
the observed magnitude of excitatory synaptic inputs (Neuropharmacology (2002) 43: 503-510). 
We have attempted to replicate these experiments (see Fig. 2A in the above paper) but without 
the use of GABAA receptor blockade. Instead, we have used an intracellular pipette solution 
containing 10mM [Cl-] and clamped the neuronal membrane potential to that of calculated EGABA 
(-70mV). Thus, with dFGABA (driving force, the difference between Vm and EGABA) being 0mV, there 
should be no IGABA and the only recorded activity should be glutamate-mediated (EAMPA and 
ENMDA are around 15 mV). Unfortunately, our experiments failed to confirm the findings of Hajos 
and Freund (Fig. 1 below) 
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Fig. 1 - Summary mean data figure 
of 8 experiments, where after 
recording a 5-minute control 
period, 2µM WIN 55-212,2-
containing solution was washed in. 
EPSCs were evoked by a 1 ms 
stimulation pulse delivered via a 
theta-glass pipette in stratum 
radiatum of CA1 region. 
 
 
 
 
• We have therefore attempted to elucidate the net effect of endocannabinoid signalling on 
postsynaptic excitability using yet another experimental protocol: 
Clamping the postsynaptic membrane to the Cl- reversal potential and eliminating inhibitory 
currents still leaves another function of inhibitory neurotransmission unaffected. Even if GABAA 
receptor activation does not result in a Cl- current and subsequent membrane potential change, 
the opening of the Cl- ion channel still results in the decrease in the membrane’s input resistance 
(Rin). Such a decrease serves to change the filtering properties of the membrane, affecting other 
synaptic currents travelling along the dendrite, in the effect known as shunting. Shunting has 
been suggested to be a major effect of inhibitory neurotransmission (Borg-Graham et al. Nature 
(1998) 393: 369–373; Mitchell SJ & Silver RA, Neuron (2003) 38: 433–445; Prescott SA & de 
Koninck Y, Proc Natl Acad Sci USA (2003) 100: 2076–2081). 
Assuming that shunting is unaffected by our experimental protocol, it Is theoretically possible to 
record any net effect of postsynaptic endocannabinoid release on the total excitatory input. One 
might expect that by inducing DSI and reducing the inhibition’s shunting effect, the observed 
excitatory currents might become enhanced during the duration of DSI. We have, therefore, 
recorded spontaneous excitatory currents (sEPSCs) in a postsynaptic cell prior to and after 
inducing a standard DSI protocol (1s, 
0mV). Unfortunately, such a protocol 
failed to uncover any changes in 
excitatory neurotransmission. Aβ also 
failed to induce a significant change in 
such a protocol (Fig. 2): 
 
Fig. 2 - Mean summary graph of such 
experiments. Standard DSI protocol fails 
to induce any observed changes in 
excitatory spontaneous activity (black 
trace, n = 10). Pre-incubation in 1uM Aβ 
does not result in additional change (red 
trace, n = 12). 
 
While our preliminary results failed to elucidate the net effect of cannabinoid signalling on 
excitability, these do not mean that the effect is in itself absent – only that given the experimental 
constraints it is difficult to manipulate the network environment without introducing unpredictable 
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variables. As our present manuscript focuses on Alzheimer’s effects on the brain’s endocannabinoid 
signalling system, we feel that a full examination of the net effect on wider network activity requires a 
larger, detailed and separate study. 
 
Q6: ‘"Mean age of death" is abbreviated as mad, but the same abbreviation is used for "mild AD", which 
is a bit confusing.  In addition, "severe AD" is abbreviated as sAD. I find it somewhat disconcerting that 
the carriers of AD might appear in the text as "mad" and "sad".’ 
 
Thank you for drawing our attention to these inevitably disturbing details. 
 
• We have spelled out ‘mean age of death ‘ throughout the manuscript, 
• We have replaced ‘mAD’ by ‘B2-4’ (referring to Braak stages 2-4). ‘B6’ (Braak stage 6) is used 
instead of ‘sAD’ throughout. 
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Specific responses to Referee 2: 
 
Thank you for your positive and supportive comments on our manuscript. We appreciate your balanced 
review, constructive criticism and suggestions. Please find our detailed responses to your specific 
queries as follows: 
 
Q1A: ‘some important quotations are missing, whilst others have been made but seem to have been 
underestimated. In the conception of this study, the authors must have been at least minimally inspired 
by the previous findings that: a) CB1 receptor blockade reduces memory retention loss in a mouse model 
of Aβ(1-42)-induced neurotoxicity (Mazzola et al., Eur J Pharmacol 2003; Micale et al, Pharmacol Res 
2010); b) sterotaxic injection of Aβ(1-42) in rats induces a transient elevation of DAGLa expression and 2-
AG levels (van der Stelt et al., Cel Mol Life Sci 2010, already quoted by the authors). This latter study 
demonstrated that elevation of endocannabinoid levels is not always beneficial towards memory 
retention loss in mice, and needs to be carried about early, in order to reduce this symptom, whereas, if 
occurring too late after the insult, it contributes to memory retention loss. This concept is very 
important, and should have been mentioned, together with all the above papers, already in the 
Introduction.’ 
 
Thank you for bringing these points to our attention. Indeed, we have discussed these concepts only in 
the ‘Discussion’ of our original submission. Our reason was to minimize the length of the ‘Introduction’. 
In the revised manuscript we have: 
 
• inserted an additional introductory paragraph to introduce the above concepts (text in blue on 
page 4), 
• referenced the above work (including Mazzola et al, 2003; Micale et al., 2010) 
• logically linked existing evidence on endocannabinoid functions in Alzheimer’s and its 
experimental models with our specific aims. 
 
Q1B: ‘Instead, the authors, whose findings strongly support this concept, and provide the underlying 
mechanisms, do not even mention that the idea that endocannabinoids are not only beneficial (as 
suggested by Ramirez et al and Palazuelos et al) via CB2 receptors in animal models of AD, but can also 
contribute to symptoms in advanced AD via CB1, was already put forward in these previous papers; this 
concept is also highlighted in a review article by Bisogno and Di Marzo, Curr Pharm Des. 2008, that 
again the authors should quote.’ 
 
• We discuss the role of CB1 and CB2 cannabinoid receptors and the possible contribution of 
endocannabinoid signalling to worsen AD symptoms on page 4. 
• We have referenced the above review when formulating our introductory statement. 
 
Q2: ‘the authors have used URB602 at a very high concentration to gain evidence that the 2-AG 
hydrolysing activity that augments in cytosolic fractions and is reduced in the plasmalemma is at least in 
part due to MAGL. Indeed, much better tools (more potent and more selective), such as JZL184 and 
OMDM166 (Long et al., Nat Chem Biol. 2009; Bisogno et al., Biochim Biophys Acta 2009) have been 
developed. If the authors cannot perform experiments with these tools, or with a selective FAAH 
inhibitor too, they should reconsider entirely their conclusion that the 2-AG hydrolysing activity they are 
measuring is partly due to MAGL, also because evidence exists for a strong upregulation of FAAH in AD 
plaques from post-mortem brain (Benito et al). Furthermore, there is really no evidence in the literature 
that cytosolic 2-AG hydrolysing activities do not contribute to 2-AG inactivation in neurons and 
microglia.’ 
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We have performed all experiments and added corresponding data to the revised manuscript, 
including: 
 
• MGL inhibition by JZL184. We used JZL184 at a final concentration of 5 µM to selectively inhibit 
MGL. Data from these experiments corroborate our previous findings with URB602. 
• replacing Fig. 7C,C1 by corresponding data upon JZL184-induced MGL inhibition. 
• moving experimental data with URB602 to Supplementary Fig. 8B,B1. 
• providing Western blot data on FAAH levels in Alzheimer’s (Braak II-IV and Braak VI) and age-
match control tissues (Supplementary Fig. 5A-B1), 
• performing experiments with URB597 and showing that i) FAAH does not contribute to 
degrading 2-AG in Alzheimer’s brain (Fig. 7D), 2) FAAH enzymatic activity decreases in 
Alzheimer’s disease (Supplementary Fig. 8C). 
• modifying our statement on the importance of the subcellular segregation of MGL activities to 
particularly focus on 2-AG inactivation that targets transmembrane receptors during retrograde 
signalling. 
 
Q3: ‘van der Stelt et al., 2006, also showed that a late decrease of anandamide levels in the ipislateral 
hippocampus occurs in rats injected with Aβ(1-42). Did the authors measure metabolic enzymes for 
anandamide at all? Likewise, did the authors measure CB2 expression or that of TRPV1 (another 
endocannabinoid target recently suggested to participate in memory control, see Micale et al., 
Pharmacol Res 2010). Even negative results should be provided if obtained by the authors. At any rate 
this previous finding of the changes of the other endocannabinoid (going in an opposite direction to 2-
AG) should be quoted’ 
 
During the revision process, we have performed extensive experimentation to extend existing 
knowledge on modifications to anandamide metabolism and signalling in Alzheimer’s disease. Our 
results include: 
 
• Western analysis of FAAH levels (AEA degradation) in Alzheimer’s (Supplementary Fig. 5A-B1), 
• Western analysis of NAPE-PLD levels (one of the putative enzymes involved in AEA synthesis) in 
Alzheimer’s subjects and age-matched controls (Supplementary Fig. 5A,C,C1), 
• histochemical localization of TRPV1-like immunoreactivity in human brain and identification of 
a postsynaptic (dendritic) expression locus (Supplementary Fig. 5D-E2). We have been advised 
on the choice of anti-TRPV1 antibody, including knock-out verification of signal specificity by 
Drs. Vincenzo Di Marzo and Istvan Katona, leading experts in the study of 
endovanilloid/endocannabinoid signalling networks, 
• TRPV1 ligand binding experiments, showing the lack of a progressive change in TRPV1 binding 
in Alzheimer’s, 
• reference to Micale et al., 2010, 
• an introductory statement at the ‘Results’ section to justify why these data are only showed in 
Supplementary Information, 
• detailed description of the methods involved, 
• references to our recent work (Halleskog et al., Glia, 2011) showing increased CB2 cannabinoid 
receptor expression in Alzheimer’s disease, 
• highlighting differential modifications to 2-AG and AEA signalling in the ‘Abstract’. 
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Q4: ‘no idea of the post-mortem delay of the human brains used for this study is given in the Methods. 
This is an important issue since post-mortem can alter the levels of endocannabinoids.’ 
 
• Post-mortem delay is one key parameter shown in Supporting Table 1 (please see ‘PMD’ label). 
• We have referenced the work of Miklos Palkovits and colleagues showing opposing and 
regional post-mortem changes in AEA and 2-AG levels in human brain. 
• We have provided regression plots for each biochemical marker (see: Fig. 6A2, Supporting Figs. 
S1, S4, S5) to exclude a relationship between protein levels and post-mortem delay. 
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3 
Abstract 
Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, 
thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol (2-AG), an 
endocannabinoid, is one such messenger produced in the postsynapse that inhibits 
neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors (CB1Rs). Cognitive 
impairment in Alzheimer’s disease (AD) is due to synaptic failure in hippocampal neuronal 
networks. We hypothesized that errant retrograde 2-AG signalling impairs synaptic 
neurotransmission in AD. Comparative protein profiling and quantitative morphometry showed that 
overall CB1R protein levels in the hippocampi of AD patients remain unchanged relative to age-
matched controls, and CB1R+ presynapses engulf β-amyloid (Aβ)-containing senile plaques. 
Hippocampal protein concentrations for sn-1-diacylglycerol lipases α and β (DAGLα/β), synthesizing 
2-AG, significantly increase in definite AD (Braak stage VI), with ectopic DAGLβ expression found in 
microglia accumulating near senile plaques and apposing CB1R+ presynapses. We find that 
microglia expressing two 2-AG-degrading enzymes, serine hydrolase α/β-hydrolase domain-
containing 6 (ABHD6) and monoacylglycerol lipase (MGL), begin to surround senile plaques in 
probable AD (Braak stage III). However, AD pathology differentially impacts ABHD6 and MGL in 
hippocampal neurons: ABHD6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. 
In contrast, pyramidal cells containing hyperphosphorylated tau retain MGL expression, although at 
levels significantly lower than in neurons lacking neurofibrillary pathology. Here, MGL accumulates 
in CB1R+ presynapses. Subcellular fractionation revealed impaired MGL recruitment to biological 
membranes in post-mortem AD tissues, suggesting AD-related modifications to terminating 2-AG 
signalling. We have experimentally confirmed that altered 2-AG signalling could contribute to 
synapse silencing in AD by demonstrating significantly prolonged depolarization-induced 
suppression of inhibition when superfusing mouse hippocampi with Aβ. We propose that the 
temporal dynamics and cellular specificity of molecular rearrangements impairing 2-AG availability 
and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, 
particularly around senile plaques, can exacerbate synaptic failure in AD. 
Keywords: glia / human / neurodegeneration / retrograde signalling / synapse 
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Introduction 
Alzheimer’s disease (AD) is the most common form of age-related dementia. Although two 
competing hypothesis exist as to the molecular sequel behind neuronal demise in AD (Small and 
Duff 2008), the ultimate and invariable outcome of both intracellular tau hyperphosphorylation, and 
overt production and extracellular release of β-amyloid (Aβ) is impaired synaptic communication, 
particularly in the hippocampus (Oddo et al., 2003; Walsh and Selkoe 2004). Oligomeric Aβ can 
target excitatory synapses (Shemer et al., 2006), where Aβ disrupts the molecular machinery 
underpinning both presynaptic neurotransmitter release and postsynaptic responsiveness, thus 
impairing various forms of short- and long-term synaptic plasticity (Shemer et al., 2006; Walsh et al., 
2002). A causal relationship between Aβ-induced NMDA and AMPA receptor removal and 
dephosphorylation (Gu et al., 2009; Kamenetz et al., 2003; Hsieh et al., 2006; Snyder et al., 2005) 
and impaired intracellular Ca2+ signalling in the postsynapse (Kuchibhotla et al., 2008), 
predominantly in dendritic spines receiving excitatory inputs, has been identified as a determinant of 
Aβ-induced synaptic dysfunction. 
The temporal dynamics of neurotransmitter release at both excitatory and inhibitory synapses are 
controlled by retrograde signalling networks (Alger 2002), with retrograde messengers liberated 
from the subsynaptic dendrite in temporal cohesion with postsynaptic spike timing (Kano et al., 
2009). Endocannabinoid signalling is one such mechanism widely distributed in rodent (Katona et 
al., 2006), primate (Harkany et al., 2005) and human brains (Ludanyi et al., 2010). Transgenic 
analyses (Gao et al., 2010; Tanimura et al., 2010) reveal that 2-arachidonoyl glycerol (2-AG) is a 
particularly efficacious endocannabinoid to tune synaptic communication in the hippocampus. The 
canonical pathway of 2-AG metabolism posits 2-AG synthesis by Ca2+-dependent sn-1-
diacylglycerol lipases α and β (DAGLs) (Bisogno et al., 2003), with DAGLs anchored at the neck of 
dendritic spines (Uchigashima et al., 2007). Once released, 2-AG engages CB1 cannabinoid 
receptors (CB1Rs) at glutamatergic as well as GABAergic presynapses (Kano et al., 2009). 
Monoacylglycerol lipase (MGL) (Dinh et al., 2002) and the serine hydrolase α/β-hydrolase domain-
containing 6 (ABHD6) are recruited to pre- (Hashimotodani et al., 2007) and postsynaptic sites 
(Marrs et al., 2010), respectively, to terminate 2-AG signalling. 
Age-related learning and memory deficits upon CB1R deletion (Bilkei-Gorzo et al., 2005) or 
phytocannabinoid administration (Wise et al., 2009) illustrate the physiological significance of 
endocannabinoid signalling in the aging brain. In AD, endocannabinoids may exert dual roles 
(Bisogno and Di Marzo 2008): increased endocannabinoid availability appears beneficial in 
reducing pro-inflammatory microglia transformation and activity through a CB2 cannabinoid receptor 
(CB2R)-dependent mechanism (Ramirez et al., 2005; Halleskog et al., 2011). Alternatively, CB1R 
modulation can gate Aβ neurotoxicity and protect against Aβ-induced amnesia in hippocampal 
learning tasks (Mazzola et al., 2003; Micale et al., 2010). Whilst CB1R activation during ongoing 
neurodegeneration clearly improves cognitive outcome by inhibiting neuronal apoptosis and gliosis, 
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5 
CB1R agonist administration during advanced neurodegeneration could instead worsen Aβ-induced 
neuronal demise by inhibiting residual neuronal activity (van der Stelt et al., 2006). Nevertheless, 
experimental evidence unequivocally identifying the impact of Aβ on endocannabinoid-mediated 
forms of hippocampal synaptic plasticity is as yet lacking. 
Modifications to CB1R expression and signalling efficacy in AD are ambiguous (Westlake et al., 
1994; Lee et al., 2010). In addition, coordinated expression and subcellular distribution of CB1Rs, 
DAGLs, ABHD6 and MGL, and their relationship to retrograde signalling in AD remain essentially 
unexplored. We hypothesized a functional relationship between errant 2-AG signalling and synaptic 
impairment in AD: Aβ could impact Ca2+-dependent 2-AG synthesis and release, while cytoskeletal 
damage might alter subcellular DAGL, MGL and/or ABHD6 recruitment, thus disrupting the 
dynamics of 2-AG signalling. Irrespective of the primary pathogenic cascade, molecular 
reorganization of 2-AG signalling networks might be detrimental to maintain synaptic 
responsiveness and plasticity. We have tested these hypotheses by dissecting the molecular 
machinery of 2-AG signalling in post-mortem human brains with AD pathology, in transgenic mouse 
models and upon acute Aβ challenge to hippocampal neurons. 
Materials & Methods 
Human tissues. Hippocampal tissue samples were obtained from AD patients and age-matched 
controls (without clinical signs of neuropsychiatric disease) at the London Neurodegenerative 
Diseases Brain Bank (Table S1). Neuropathological and histochemical examination, including 
classification of Aβ plaque burden (Fig. S1A), tau pathology (Table S1) and synaptic impairment 
(Fig. S1B-E), was performed as described (Supplementary Information). Tissue blocks or entire 
hippocampi were immersion fixed in 4% paraformaldehyde in 0.1M phosphate buffer (PB, pH7.4) 
for 48-72h at 4 oC followed by long-term storage in PB to which 0.1% NaN3 had been added. 
Alternatively, native tissue blocks (2-3 cm3) of ~1 cm thickness from the other hemisphere were 
stored at -80 oC until processing for biochemical analysis. 
APdE9 mice. Male APPswe/PS1dE9 (APdE9) transgenic mice and littermate controls (WT) aged 7 
or 14 months were used (n = 26 animals in total; ethical documentation of in vivo studies can be 
found in Supplementary Information). APdE9 mice were generated by heterozygously co-
expressing mutant amyloid precursor protein (APP, KM593/594NL) and an exon 9 deletion variant 
of presenilin 1 (PS1), both associated with familial AD (Jankowsky et al., 2004). 
Immunohistochemistry and imaging. Multiple immunofluorescence histochemistry on human 
temporal lobe sections containing the hippocampal formation was performed by applying select 
combinations of primary antibodies (Fig. S2, Table S2) according to standard protocols (Halleskog 
et al., 2011; Harkany et al., 2003; Harkany et al., 2005; Keimpema et al., 2010). Single x-y plane or 
orthogonal z image stacks were captured, after quenching tissue autofluorescence (Fig. S3), by 
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6 
laser-scanning microscopy (710LSM, Zeiss) as described in Supplementary Methods. Three-
dimensional reconstruction and rendering of dendrite segments to specify the spatial relationships 
of DAGLα/DAGLβ or MGL immunoreactivities was performed using the BioVis3D reconstruction 
package (Montevideo, Uruguay) according to specific imaging criteria (Supplementary Methods). 
Acute brain slice preparation and electrophysiology. Patch clamp recordings, differential 
interference contrast imaging and stimulus protocols in hippocampal slices from postnatal 14- or 16-
day-old mouse brains were performed as described (Supplementary Methods). 
Western blotting. Protein samples prepared from human or mouse hippocampi were analyzed 
under denaturing conditions. Western blot analysis was undertaken as described (Supplementary 
Methods) with primary antibodies listed in Table S2. Blots were scanned on a Lycor Odyssey-IR 
imager and quantified by using ImageJ1.32j. 
WNT-3A stimulation and gene expression profiling in microglia. Primary microglia were 
isolated from newborn mouse brains (Halleskog et al., 2011). Cultures typically contained >95% 
microglia, as validated by cytochemistry using Griffonia simplicifolia isolectin B4 (Sigma). Three 
independent harvests of primary microglia were seeded in six well plates and challenged 24h after 
plating. Serum-deprived microglia were treated with either 0.1% BSA (vehicle control) or 300 ng/ml 
recombinant WNT-3A for 6h. RNA was prepared and analyzed on an Affimetrix Mouse Gene 1.0 ST 
Array (Halleskog et al., 2011). Real-time, quantitative PCR (qPCR) analysis was performed as 
reported earlier with custom-designed primers (Keimpema et al., 2010). N13 microglia-like cells 
(Halleskog et al., 2011) were exposed to fibrillar Aβ(1-42) at 100 nM final concentration for 48h. 
2-AG degradation in Alzheimer’s brains. Biochemical studies were conducted in an independent 
cohort of human cortical samples (see Supplementary Information for details). 
Neurohistopathological evaluation and disease classification were as above. Frontal cortices were 
mechanically homogenized (10%) in Tris HCl (20 mM, pH 7.2) containing 0.32 M sucrose and 
protease inhibitors, and centrifuged to eliminate nuclei and cellular debris (1,000g, 10 min, 4 oC). 
Supernatants were ultracentrifuged (100,000g, 60 min, 4ºC) to obtain membrane and soluble 
fractions, both presenting 2-AG-degrading activity (Blankman et al., 2007). Protein concentrations 
were determined by Bradford’s colorimetric method (Bradford 1976). 2-AG-degrading activity was 
assessed by incubating sample fractions (10 µg protein) in a solution containing Tris HCl (10 mM, 
pH 7.2), 1 mM EDTA, fatty acid-free BSA (1.25 mg/ml), [3H]2-AG ([1,2,3-3H]glycerol, 25 µM, 40 
Ci/mmol specific activity; New England Nuclear) in a final volume of 200 µl for 15 min at 37ºC. 
Identical conditions were used to assess anandamide (AEA) degrading activity using [3H]AEA ([1-
3H]ethanolamine, 25 µM, 40 Ci/mmol specific activity; ARC Inc). Reactions were stopped by 400 µl 
chloroform:methanol (2:1, v/v) and vigorous vortexing. Fractions either containing [1,2,3-
3H]glycerol/[1-3H]ethanolamine (top) or non-hydrolyzed [3H]2-AG/[3H]AEA (bottom/organic) were 
separated by centrifugation (2,000g, 10 min, 4 oC), transferred into scintillation vials and 
radioactivity measured by liquid scintillation spectroscopy. Actual experimental conditions were 
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7 
selected from pilot experiments assaying the relationship of substrate and protein concentrations to 
identify optimal 2-AG-degrading enzymatic activity (data not shown), and favoured assay conditions 
allowing ~50% of 2-AG converted into glycerol in membrane fractions from control brains. JZL184 
(5 µM; (Long et al., 2009)) or URB602 (1 mM; (King et al., 2007)) served to determine the specific 
contribution of MGL to 2-AG degradation. URB597 (20 nM; (Mor et al., 2004)) was used to test the 
changes in AEA-degrading activity in AD brains. Enzyme activity was expressed as pmol [1,2,3-
3H]glycerol formed/mg protein/15 min and [3H]ethanolamine formed/mg protein/15 min, respectively. 
Human Aβ(1-40) was from PolyPeptides (France) and diluted and used as described for Aβ(1-42) 
(Supplementary Methods). Methods to assess TRPV1 transient receptor potential cation channel 
binding in post-mortem hippocampal samples are provided in Supplementary Information. 
Statistical analysis. Data were analyzed using SPSS 17.0 (SPSS Inc.). Integrated optical density 
of immunoreactive targets in Western blot experiments, and decay constants from electrophysiology 
measurements were evaluated using Student’s t-test (on independent samples). Linear regression 
analysis of CB1R, DAGLs and MGL isoforms, synaptic markers, disease stages and/or post-mortem 
delay (Fig. S4) was performed by defining Pearson’s correlation coefficient. Data were expressed 
as mean ± s.e.m. A p value of < 0.05 was considered statistically significant. 
Results 
Here, we focus on molecular rearrangements of 2-AG signalling networks affecting synaptic 
neurotransmission during AD pathology in human brain and experimental models of Aβ 
synaptotoxicity. Nevertheless, we present data on N-acyl-phosphatidylethanolamide-specific 
phospholipase D (NAPE-PLD), fatty-acid amide hydrolase (FAAH) and TRPV1 significantly 
extending available knowledge on AD-related modifications to AEA signalling (Ramirez et al., 2005; 
Benito et al., 2003) in Fig. S5. Changes of CB2R expression in this AD cohort have recently been 
reported elsewhere (Halleskog et al., 2011). 
CB1R expression is unchanged in Alzheimer’s disease 
Cellular mapping studies combined with ultrastructural analysis unequivocally position CB1Rs 
presynaptically in both excitatory and inhibitory nerve endings of rodent (Katona et al., 2006), 
primate (Harkany et al., 2005) and human hippocampus (Ludanyi et al., 2010). However, the impact 
of aging or AD pathology on CB1R expression and (sub-)cellular distribution in the human 
hippocampus remain ambiguous (Westlake et al., 1994; Lee et al., 2010). 
We have studied clinicopathologically-verified patient material consisting of 10 subjects classified as 
controls (≤ Braak I stage) aged 52-96 years, 9 subjects presenting Braak stage III/IV pathology (B2-
4) and aged 72-105 years, as well as 9 patients with pathological indices of Braak stage VI (B6) and 
aged 69-90 years (Table S1). B2-4 and B6 patients had significantly increased Aβ levels (Fig. S1A) 
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8 
and synaptic modifications as suggested by decreased levels of synaptosomal-associated protein of 
25 kDa (SNAP25) (Garbelli et al., 2008) and PSD95 (Sampedro et al., 1982), pre- and postsynaptic 
markers, respectively (Fig. S1C,D). 
Western analysis demonstrated CB1R expression in the aged human hippocampus (Fig. 1A). 
CB1Rs were of 52 kDa molecular weight suggesting that mature, non-truncated receptors were 
detected in post-mortem brain homogenates (Fig. 1A,B). CB1R levels remained unchanged in 
patients with B2-4 or B6 pathology (Fig. 1B). We performed correlation analysis between SNAP25 
and CB1Rs to test whether individual variations in CB1R levels may be related to those of SNAP25 
or PSD95 at excitatory synapses. However, CB1R expression did not correlate with that of either 
SNAP25 (Fig. S1E) or PSD95 (data not shown). 
Immunohistochemistry revealed a dense meshwork of CB1R+ axons with CB1Rs particularly 
enriched in presynapses that contained synaptophysin, a pan-presynaptic marker (Schubert et al., 
1991), in the strata pyramidale and radiatum of the CA1-3 subfields (Fig. 2A,B; Fig. S6A-A3), and 
the stratum moleculare of the fascia dentata (Fig. S7A) of aged human subjects. High-resolution 
laser-scanning microscopy confirmed that CB1Rs localized to synaptophysin+ presynapses targeting 
either the perisomatic segment (Fig. 2C-C3) or distal dendrites (Fig. 2D-D3) of pyramidal neurons. 
Accordingly, CB1R+/microtubule-associated protein 2+ (MAP2+) double-labelled structures were not 
observed (MAP2 is a ubiquitous somatodendritic marker of neurons (Peng et al., 1986)). CB1R 
distribution in B2-4/B6 cases was unaltered: CB1R+ axons coursed in both soma-rich laminae, 
including the stratum granulosum (Fig. 2E) and receptive fields (e.g., stratum moleculare; Fig. 2E). 
Notably, CB1R+ axons appeared to engulf senile plaques (Fig. 2E1-E3) with CB1R+ bouton-like 
varicosities commonly situated within the Aβ-dense plaque cores. Therefore, we conclude that 
CB1R expression and axonal distribution remain largely unchanged in AD, as compared to age-
matched controls. 
DAGLβ but not DAGLα redistribution in Alzheimer’s disease 
The long-held view of 2-AG biosynthesis posits DAGLs as Ca2+-regulated enzymes synthesizing 
this endocannabinoid (Bisogno et al., 2003). DAGLs reside in the perisynaptic annulus, a proximal 
zone surrounding the postsynaptic density at CB1R+ excitatory synapses (Uchigashima et al., 
2007), also in human brain (Ludanyi et al., 2010). Epilepsy-induced sclerotic neurodegeneration in 
human brain reduces DAGLα but not DAGLβ expression by ~60% suggesting that impaired 2-AG 
synthesis may occur under disease conditions (Ludanyi et al., 2008). 
We have tested this possibility by analyzing DAGLα and DAGLβ protein expression in B2-4, B6 and 
age-matched control brains (Fig. 1A and C,C1). We find a gradual increase in the protein levels of 
both enzymes, paralleling AD progression (DAGLα: 145.4 ± 50.9% of control, n = 7 [B2-4], 193.9 ± 
41.9% of control, n = 6, p = 0.076 vs. control [B6]; DAGLβ: 155.1 ± 29.1% of control n = 7 [B2-4]; 
175.9 ± 23.7% of control n = 6, p = 0.015 vs. control [B6]; Fig. 1C,C1). Next, we have explored 
whether DAGLα expression correlates with that of DAGLβ. Analysis of discrete subject cohorts 
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9 
revealed the lack of an expressional relationship between the two enzymes in control or B2-4 brains 
(Fig. 1D). In contrast, we find a strong inverse relationship between DAGLα and DAGLβ protein 
levels in B6 brains (Fig. 1D). These findings suggest that either DAGLα is replaced by DAGLβ 
postsynaptically or DAGLα and DAGLβ segregate to distinct cell types with independent 
expressional control for DAGLs in AD. 
Multiple immunofluorescence histochemistry using affinity-pure antibodies (Fig. S2), and 
appropriate histochemical (Fig. S3)/imaging (Fig. S6B) controls, in the CA1-CA3 of the aged human 
hippocampus and fascia dentata (Fig. 3A and S7B-B2) revealed DAGLα+ and DAGLβ+ puncta along 
the dendritic trees of pyramidal neurons (Fig. 3B-B2) and granule cells (Fig. S7B-B2). The density of 
DAGLα+ puncta exceeded that of DAGLβ+ structures (Fig. 3B-B2,C1-C3 and E1). High-resolution 
microscopy along individual MAP2+ dendrite segments showed frequent DAGLα/DAGLβ co-
localization (Fig. 3C-C3). Three-dimensional reconstruction of select dendrites upon capturing 
consecutive images in orthogonal stacks verified that both DAGLα and DAGLβ were localized 
within dendritic compartments and accumulated at the stem of dendritic spines (Fig. 3D,D1). 
Quantitative morphometry showed that the Pearson’s correlation coefficient of dual-labelled 
structures only marginally differs from 0, suggesting limited (if any) positive correlation (co-
regulation) between signal intensities for DAGLα and DAGLβ (Fig. 3E). We quantitatively verified a 
higher density of DAGLα than DAGLβ along apical dendrite profiles of pyramidal cells in the CA1 
stratum radiatum (Fig. 3E1 and see 3B-B2). Here, 24.0 ± 3.9% of DAGLα+ postsynaptic (MAP2+) 
puncta contained DAGLβ (Fig. 3E2). In contrast, 47.7 ± 3.1% of DAGLβ+ structures were dual 
labelled, suggesting that DAGLα can drive DAGLβ recruitment to sites of co-localization. 
The distribution of DAGLα immunoreactivity remained largely unchanged in AD, including around 
senile plaques where DAGLα immunoreactivity has been found scattered in Aβ-laden territories 
(Fig. 3F). In contrast, DAGLβ immunoreactivity accumulated in small-diameter cell-like structures 
associated with senile plaques and apposing CB1R+ axons (Fig. 3F1,F2). By using ionized Ca2+-
binding adaptor molecule-1 (IBA-1) we demonstrate that activated microglia (Xu et al., 2008) 
frequently surrounding senile plaques express DAGLβ in B6 brains (Fig. 3G-G2). Together, these 
findings suggest that both DAGLs can co-exist in dendritic spines of hippocampal neurons in the 
aged human hippocampus. In addition, microglia represent a novel cellular component participating 
in 2-AG biosynthesis in AD. The specific accumulation of DAGLβ+ microglia around senile plaques 
could lead to the focal enhancement of 2-AG signalling, affecting neuronal excitability (Busche et 
al., 2008), unless compensated by molecular rearrangements in 2-AG degrading enzymatic 
capacity in AD brains. 
ABHD6 expression in Alzheimer’s disease 
ABHD6 is a recently characterized serine hydrolase degrading 2-AG in the nervous system (Marrs 
et al., 2010). While activity-based protein profiling identified ABHD6 as a candidate to hydrolyze 2-
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10 
AG in microglia-like cells, follow-up histochemical studies in rodent brain identified the 
somatodendritic domain of neurons as major, postsynaptic foci accumulating ABHD6 (Marrs et al., 
2010). Western blotting demonstrated that ABHD6 protein is present in the aged human 
hippocampus (Fig. 1A,E). Comparative analysis revealed unchanged ABHD6 levels across B2-4, 
B6 and age-matched control tissues (Fig. 1A,E). However, these findings do not exclude the 
possibility that neuronal and glial ABHD6 expression differentially contribute to total ABHD6 levels 
in control vs. AD brains. 
We show, by using affinity-pure anti-ABHD6 antibodies (Marrs et al., 2010), ABHD6-like 
immunoreactivity decorating the somatic membrane and apical dendrites of pyramidal cells in the 
hippocampus of aged humans (Fig. 4A-A2). We find AD progression associated with a gradual 
decrease of ABHD6-like immunoreactivity in hippocampal neurons (Fig. 4B,B1). Notably, the 
distribution of ABHD6 and AT8, the latter identifying tau hyperphosphorylated at Ser202/Thr205 
residues in degenerating neurons (Goedert et al., 1989), is mutually exclusive in B6 brain, 
suggesting that AD-related cytoskeletal damage can arrest ABHD6 expression (Fig. 4C,C1). In 
contrast, ABHD6+ small diameter, multipolar cells lacking MAP2 accumulate in AD brains (Fig. 
4B,B1). We demonstrate that microglia can express ABHD6 (particularly in B6) by revealing an 
intricate network of ABHD6+/IBA1+ but MAP2- microglia end-feet scattered around hippocampal 
neurons (Fig. 4B1,B2). In addition, we find that Aβ-containing neuritic plaques attract ABHD6+/IBA1+ 
microglia, which accumulate both around and within senile plaques (Fig. 4D-D3). In summary, our 
data uncover a postsynaptic expression site for ABHD6 in neurons of the aged human 
hippocampus, as well as widespread ABHD6 expression by activated microglia in AD. 
MGL is recruited to presynapses and astroglia in aged human brain 
Although MGL has many substrates (Nomura et al., 2010), it is considered to be the major enzyme 
inactivating >80% of 2-AG in adult rodent brain (Blankman et al., 2007). Chronic CB1R 
desensitization due to increased 2-AG but not other bioactive lipid levels in MGL-/- mice confirms 
that 2-AG is primarily degraded by MGL in the nervous system (Schlosburg et al., 2010). MGL is 
localized to presynapses in rodent (Dinh et al., 2002) and human brains (Ludanyi et al., 2010). 
However, MGL expression and subcellular localization during aging and AD remain elusive. 
We find, by using two antibodies directed against non-overlapping MGL epitopes and validated in 
MGL-/- mice ((Keimpema et al., 2010); Fig. S2), prominent MGL immunoreactivity at three sites in 
the aged human hippocampus: i) the somatic region of dentate granule cells (Fig. 5A-B1) and CA1 
pyramidal neurons (Fig. 5C); ii) nerve endings concentrating in the stratum moleculare of the 
dentate fascia (Fig. 5B1) and the stratum radiatum of the CA subfields (Fig. 5C); iii) astroglia-like 
cells randomly distributed across hippocampal laminae (Fig. 5B1,H). Somatic MGL immunoreactivity 
in pyramidal cells is primarily present in the cytosol (Fig. 5D-D3). Although moderate MGL 
immunoreactivity was occasionally seen in the proximal segment of apical dendrites, overall MGL is 
absent in the dendritic tree of principal neurons (Fig. 5C). MGL ubiquitously co-exists with CB1Rs in 
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11 
presynapse-like puncta apposing pyramidal cells’ dendrites, suggesting that MGL retains its 
presynaptic localization in the aged human hippocampus (Fig. 5E-E3). We have confirmed our 
histochemical findings by three-dimensional reconstruction of pyramidal cell dendrites and 
perisynaptic astroglia end-feet (Fig. 5F,F1) and find a complete lack of co-localization between MGL 
and MAP2, a somatodendritic marker of neurons (Peng et al., 1986), as well as glial fibrillary acidic 
protein (GFAP) in astroglia. 
Next, we asked whether MGL and CB1Rs co-exist throughout the hippocampal parenchyma or are 
only recruited to synaptic terminal-like specializations apposing MAP2+ somatodendritic elements. 
Quantitative immunofluorescence morphometry (Fig. S6C) revealed moderate correlation between 
the intensities of MGL and CB1R immunoreactivities at sites of co-localization (Fig. 5G), suggesting 
that recruitment of the two markers to the same sites may proceeds largely independently of one 
another. Next, we find that the area occupancy of MGL immunoreactivity exceeds that of the CB1R 
(Fig. 5G1) implying differences between the axonal transport, overall expression levels or 
subcellular recruitment of MGL and CB1R in the aged human brain. Accordingly, we find that only 
12.6 ± 1.2% of MGL+ structures are labelled for CB1Rs. In contrast, 25.1 ± 2.2% of CB1R 
immunoreactivity co-localizes with that of MGL (Fig. 5G2). Thus, our data suggest that MGL can 
accumulate in CB1R+ presynapses in the human hippocampus to terminate retrograde 2-AG 
signalling. 
We used Western analysis to compare MGL protein levels in B2-4 and B6 patients as well as age-
matched controls, and find significantly increased levels of both major MGL isoforms in B6 brains 
(Fig. 1A,F,F1). Correlation analysis substantiated a positive relationship between expression levels 
of the two major MGL isoforms (Fig. 1G). Next, we have refined these results by verifying that 
advancing Braak stages in AD couples to gradually increased MGL levels in an isoform (Fig. 6A,A1) 
and post-mortem delay (Fig. 6A2)-independent manner. Since we performed Western analysis on 
total protein samples from human brain several open questions remained including: whether i) 
increased MGL concentrations represent novel expression sites as a result of ongoing 
neurodegeneration as well as neuroinflammation in AD, ii) defunct neurons presenting cytoskeletal 
abnormalities, such as hyperphosphorylated tau, lose MGL expression as seen for ABHD6, iii) AD 
impacts the metabolic competence of MGL by impairing its recruitment to the plasmalemma. 
In the Alzheimer’s hippocampus, we find that MGL+/IBA1+ microglia cells accumulate around senile 
plaques (Fig. 6B,B1). Although quantitative morphometry was not an objective of the present report, 
a clear increase in the density of MGL+ microglia can be seen when comparing B2-4 vs. B6 brains. 
Hippocampal principal cells – both pyramidal cells of the CA subfields and dentate granule cells – 
express MGL. We find that AT8+ pyramidal cells retain MGL expression (Fig. 6C-C2’), although at 
significantly lower levels than those without intracellular tau pathology (Fig. 6D; 121.85 ± 3.73 grey 
scale unit [AT8- neurons] vs. 81.75 ± 8.31 grey scale unit [AT8+ neurons]; p < 0.001). Our data 
cumulatively indicate that both microglia (Fig. 6B) and astroglia (Fig. 5H) can serve as sources of 
MGL, and a progressive shift of MGL expression from damaged neurons to activated micro- and 
astroglia occurs in AD. 
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12 
Gene expression profiling in mouse microglia 
Activated microglia have previously been shown to express CB2Rs in AD (Ramirez et al., 2005; 
Benito et al., 2003) or Down’s syndrome (Nunez et al., 2008), and pharmacological challenges can 
increase 2-AG production in this cell type (Walter et al., 2003). However, co-existence of molecular 
components determining an operational 2-AG signalling network in activated microglia (that is, 
CB1Rs/CB2Rs, DAGLs, ABHD6 and MGL) capable to sustain autocrine and/or paracrine 2-AG 
signalling remains unknown. We performed Affymetrix gene expression profiling coupled to qPCR 
analysis (Fig. 7A) to test the expression of CB1Rs, CB2Rs, as well as 2-AG metabolic enzymes in 
primary mouse microglia under experimental conditions mimicking pro-inflammatory transformation 
in AD brains (Halleskog et al., 2011). Under control conditions, CB1R, CB2R, DAGLα, DAGLβ, MGL, 
ABHD6 and ABHD12 expression levels exceeded the detection minimum of Affymetrix chips (data 
not shown). Microglia activation can proceed through Aβ-independent mechanisms in vivo 
(Halleskog et al., 2011). Therefore, we applied WNT-3A (300 ng/ml) to induce pro-inflammatory 
transformation of primary mouse microglia. WNT-3A significantly increased mRNA transcript levels 
of interleukin 6 and tumor necrosis factor α, pro-inflammatory cytokines, relative to controls 
(Halleskog et al., 2011). Simultaneously, WNT-3A reduced CB2R, DAGLα and DAGLβ mRNA 
expression, whilst leaving CB1R, MGL and ABHD6/12 expression unchanged (Fig. 7A). Quantitative 
PCR analysis of N18 microglia-like cells exposed to fibrillar Aβ(1-40) (100 nM vs. non-treated 
controls), known to activate microglia (Ramirez et al., 2005), showed significantly decreased mRNA 
transcript levels of CB1Rs (-61.3 ± 3.1% of control; n = 4/condition; p = 0.017) and DAGLα (-35.2 ± 
6.1% of control; n = 3-4/condition; p = 0.042) but not of other molecular components of 2-AG 
signalling (CB2R: -11.6 ± 16.7%, p > 0.1, n = 4/condition; MGL: -60.3 ± 4.4%; p > 0.1, n = 
3/condition; Fig. 7A). In sum, these data demonstrate that microglia can express receptor and 
enzyme components of 2-AG signalling networks and respond to pro-inflammatory stimuli by 
transcriptional regulation of rate-limiting molecular constituents of 2-AG signalling. 
2-AG hydrolyzing activity in Alzheimer’s disease and upon Aβ exposure 
Rearrangements in 2-AG signalling networks may ultimately amplify AD-related synaptic impairment 
if subcellular enzyme redistribution is associated with impaired enzymatic activity. Acute Aβ infusion 
in the rodent hippocampus increases 2-AG concentrations, a finding that has been interpreted as an 
endogenous neuroprotective mechanism against Aβ-induced oxidative stress (van der Stelt et al., 
2006). Here, we have tested the alternative hypothesis that Aβ-induced increase in 2-AG levels 
reflects impaired 2-AG catabolism under disease conditions. We have focused on MGL as a 
candidate whose recruitment from the cytosol to its metabolically favoured position in the internal 
leaflet of the plasmalemma (Labar et al., 2010) may be impeded by Aβ-induced oxidative damage 
to biological membranes in AD (Ramirez et al., 2005; Querfurth and LaFerla 2010). 
We have measured the rate of 2-AG degradation in frontal cortices of AD patients and age-matched 
controls by determining the amount of [1,2,3-3H]glycerol after incubating membrane or cytosol 
Page 21 of 70
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Mulder et al. Brain, revised submission 
Date of submission: January 21, 2011 Research Article 
 
 
13 
fractions with [3H]2-AG. Membrane-associated 2-AG hydrolysis significantly decreased in AD, as 
compared with controls (28% of control, p < 0.05; Fig. 7B). In turn, 2-AG degrading capacity in the 
cytosol increased proportionally in AD brains relative to controls (65% of control, p < 0.05; Fig. 7B), 
suggesting the subcellular redistribution of 2-AG-degrading enzymes in human brain (total activity: 
2468 ± 96 [control] vs. 2391 ± 122 [AD] pmol 2-AG degraded/mg protein/15 min; p = 0.635, n = 
9/group). Multiple enzymes, including MGL, ABHD6 and FAAH, contribute to 2-AG degradation in 
the adult brain (Blankman et al., 2007). To assess MGL’s specific contribution to altered 2-AG 
hydrolysis in AD, we have measured the rate of [3H]2-AG degradation in the presence of the MGL 
inhibitors, JZL184 (5 µM; Fig. 7C,C1) (Long et al., 2009) or URB602 (1 mM; Fig. S9) (King et al., 
2007). We find that JZL184 inhibits 50.2% of 2-AG hydrolysis in membranes prepared from control 
brains (p < 0.01; Fig. 7C). In contrast, JZL184 inhibits only 29.6% (p < 0.05) of cytosolic 2-AG 
hydrolysis in control human cortical homogenates (Fig. 7C1). In membrane preparations from AD 
brains (Fig. 7C), 11.6% of 2-AG hydrolysis activity is eliminated by JZL184, coincident with a 
significant reduction of MGL protein levels in the cerebral cortex of AD brains (Fig. S8A-A2). 
Conversely, surplus cytosolic 2-AG hydrolysis activity in cytosol fractions of AD brains is JZL184 
sensitive (32.0%; p < 0.01 vs. vehicle-treated controls; Fig. 7C1). URB602 exhibited a similar 
pharmacological profile (Fig. S8B,B1). We excluded the contribution of FAAH to 2-AG degradation 
by showing negligible (≤10%) inhibition by URB597, a potent FAAH inhibitor (Mor et al., 2004) (see 
also Fig. S8C). These data suggest that i) MGL selectively undergoes subcellular redistribution, and 
ii) the contribution of JZL184/URB602-insensitive enzymes to 2-AG degradation (e.g. ABHD6 in 
microglia, Fig. 4B1) increases in AD. iii) FAAH - whose activity is decreased in AD (Fig. S8C) – does 
not contribute to 2-AG hydrolysis in human brain in situ. 
Next, we hypothesized that Aβ may impact the activity of enzymes involved in 2-AG hydrolysis. 
Therefore, membrane and cytosolic fractions from control brains were acutely exposed to Aβ(1-40) 
at 1 µM final concentration. Pre-incubation with Aβ(1-40) for 10 min increased 2-AG catabolism in 
both membrane and cytosol fractions of human cortices (membrane: 2118 ± 73 [control; n = 9] vs. 
2398 ± 109 [Aβ(1-40); n = 8], p = 0.045 ; cytosol: 1038 ± 41 [control; n = 9] vs. 2265 ± 112 [Aβ(1-
40); n = 9], p < 0.01; pmol 2-AG degraded/mg protein/15 min; Fig. 7E) in a shallow dose-dependent 
fashion (Fig. 7E1), thus mimicking changes in 2-AG hydrolyzing activity in AD brains. We find that 
nM Aβ(1-40) concentrations of likely pathophysiological significance (Walsh et al., 2002) can 
augment 2-AG degradation (Fig. 7E1). Thus, we conclude that Aβ contributes to the control of 2-AG 
catabolism in human brain, and reduces MGL’s 2-AG hydrolytic capacity in membrane fractions 
otherwise required to inactivate 2-AG during retrograde synaptic signalling. 
Aβ prolongs depolarization-induced suppression of inhibition 
MGL removal from the plasma membrane could increase the duration of signalling-competent 2-AG 
availability following its release from postsynaptic neurons, and prolong DSI (Kano et al., 2009). 
Consequently, enhanced 2-AG signalling could disrupt the balance between inhibitory and 
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14 
excitatory neurotransmission. A causal relationship between high focal Aβ concentration and errant 
2-AG signalling may be particularly appealing to further the mechanistic concept linking synaptic 
impairment to neuronal hyperexcitability (Busche et al., 2008; Minkeviciene et al., 2009) and 
excitotoxic neuronal damage (Mattson and Chan 2003). 
Transgenic mouse models generating age-dependent Aβ burden in the cerebral cortex and 
hippocampus, e.g. APdE9 mice (Jankowsky et al., 2004), are popular to study molecular 
pathomechanisms of AD. However, biochemical protein profiling suggests that APdE9 mice might 
be inappropriate to recapitulate molecular underpinnings of disrupted 2-AG signalling in AD (Fig. 
S9). Therefore, we have tested whether bath-applied Aβ(1-42) could acutely evoke AD-related 
subcellular rearrangements in the molecular architecture of 2-AG signalling networks. We show that 
non-fibrillar Aβ(1-42) – dissolved freshly in the superfusate (Minkeviciene et al., 2009) – facilitates 
CB1R removal from the cytosol (89.87 ± 2.29% of control; n = 5, p = 0.002; Fig. 8A,A1) and 
enrichment in membrane fractions (123.13 ± 13.26% of control) prepared from hippocampi of 
juvenile wild-type mice. Subcellular DAGLα distribution appeared stochastic with a trend towards 
cytosolic enrichment (119.76 ± 14.59%; n = 5/condition, p > 0.1; membrane fraction: 77.48 ± 
11.15%; n = 5/condition, p = 0.052; Fig. 8A,A2). Aβ(1-42) arrested MGL in the cytosol (149.16 ± 
14.59% of control; n = 6/group, p = 0.003) with unchanged membrane-associated MGL (97.95 ± 
14.60% control; p > 0.8; Fig. 8A,A3) in 1h. We hypothesized that the Aβ(1-42)-induced enhanced 
cell-surface availability of the CB1R would alter 2-AG signalling. Therefore, we sought to determine 
whether Aβ(1-42) augments the 2-AG-mediated suppression of inhibitory neurotransmission in the 
hippocampus. We have studied DSI at inhibitory synapses because Aβ(1-42) accumulation in senile 
plaques has been shown to impair GABA neurotransmission, thus provoking focal neuronal 
hyperexcitability in a transgenic model of AD (Busche et al., 2008). 
Using whole-cell patch recording of CA1 hippocampal neurons in brain slices prepared from juvenile 
mice, we elicited a baseline DSI by briefly depolarizing (1s, from -80 to 0 mV) the pyramidal cell 
(Fig. 8B). DSI was detected in all control cells, had a maximal magnitude of 25.7 ± 3.1% when 
measured between 1-5s after postsynaptic cell depolarization and normalized to the pre-
depolarization baseline (n = 9). The decay time constant (τ) of DSI was 9.15 ± 1.39 (s). Bath 
application of Aβ(1-42) for 1h did not significantly affect maximal synaptic depression in pyramidal 
cells (DSI magnitude: 32.9 ± 4.4%, n = 10, p = 0.233 vs. control; Fig. 8B1,B2). Nevertheless, the 
magnitude of synaptic depression upon non-fibrillar Aβ(1-42) pre-treatment was significantly 
different from that in control cells from 5s to 15s post-stimulus (5s: 32.5 ± 5.1% [Aβ(1-42)] vs. 18.0 ± 
5.1% [control], p = 0.039; 10s: 27.4 ± 4.3% [Aβ(1-42)] vs. 8.8 ± 0.4% [control], p = 0.004; 15s: 19.4 
± 5.7% [Aβ(1-42)] vs. 4.5 ± 4.7% [control], p = 0.047). Non-fibrillar Aβ(1-42) prolonged DSI, as 
indicated by a significant increase in its mean decay time constant (τ = 43.69 ± 11.99 (s), n = 10, p 
= 0.018 vs. control). We used AM251 (1 µM) to verify that DSI was dependent on CB1R activation 
(Fig. 8C, S10A,A1). AM251 completely abolished DSI in all cases tested. Next, we sought to 
determine whether the Aβ(1-42)-induced enhancement of DSI is exclusively due to CB1R activation 
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15 
or if Aβ(1-42) uncovers a secondary mechanism operating at hippocampal synapses otherwise 
sensitive to AM251. We find that Aβ(1-42) does not induce significant DSI in the presence of AM251 
(Fig. 8D,D1). Cumulatively, our data imply that Aβ prolongs 2-AG signalling, which will impair 
GABAergic transmission, thus contributing to the progressive development of synaptic failure in AD. 
Discussion 
This report describes significant changes to i) the molecular architecture, ii) cellular identity and iii) 
function of 2-AG metabolism in defined patient cohorts with clinicopathologically-verified AD, as well 
as in transgenic mice and acute pharmacological models of AD-like neuronal dysfunction. Although 
we cannot entirely rule out altered signal transduction downstream from CB1Rs (Lee et al., 2010), 
our biochemical and histochemical findings cumulatively highlight that 2-AG signalling in neurons is 
primarily impaired at the level of metabolic enzymatic control of 2-AG bioavailability in AD. We also 
propose that activated microglia, accumulating in AD brains and contributing to chronic 
neuroinflammation, have a fundamental role in modifying 2-AG signalling, particularly in Aβ-laden 
brain microdomains around senile plaques, and might impact synaptic communication. 
Transsynaptic 2-AG signalling in Alzheimer’s disease 
Endocannabinoids and phytocannabinoids are recognized to exert profound neuroprotection in 
models of peripheral nerve injury (Yoles et al., 1996), excitotoxicity (Khaspekov et al., 2004) and 
neurodegeneration (Palazuelos et al., 2009; Blazquez et al., 2010; Ludanyi et al., 2008) through 
CB1R/CB2R-dependent (Palazuelos et al., 2009) or -independent mechanisms (Lastres-Becker et 
al., 2005). 
In microlesion models of AD, Aβ(1-42) infusion in the rat cerebral cortex significantly increases 2-
AG but not AEA levels in the hippocampus (van der Stelt et al., 2006). This Aβ(1-42)-induced 
elevation of 2-AG concentrations is further augmented by inhibiting endocannabinoid reuptake to 
reverse hippocampal neuronal damage and decrease glial activation, thus preventing the loss of 
memory retention (van der Stelt et al., 2006). Our data are significant as they corroborate and 
notably extend the above observations by providing insights into specific AD-associated molecular 
rearrangements of 2-AG metabolism. We suggest that 2-AG biosynthesis may be enhanced by 
microglial DAGLs around Aβ-rich foci in the AD brain. In contrast, 2-AG degrading capacity in 
neurons could be substantially reduced if ABHD6 and MGL expressions are significantly 
suppressed in injured neurons with neurofibrillary pathology. Therefore, the net contribution of 2-AG 
signalling to suppressing presynaptic neurotransmitter release may be significantly increased. In 
fact, ex vivo experiments recapitulate the above scenario of Aβ-induced synaptic impairment by 
showing prolonged DSI at inhibitory afferents of CA1 pyramidal cells. Aβ-induced enhancement of 
DSI is also important to reconcile previous findings that have suggested both pre- and postsynaptic 
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16 
sites of action for Aβ when disrupting spike timing-dependent plasticity at cortical synapses 
(Shemer et al., 2006). 
Postsynaptic NMDA and AMPA receptors are widely viewed as key molecular targets of Aβ to 
disrupt synaptic plasticity (Snyder et al., 2005; Kamenetz et al., 2003; Shemer et al., 2006). In 
particular, Aβ-induced impairment of NMDA/AMPA receptor trafficking at the postsynapse can 
disrupt Ca2+ signalling in dendritic spines targeted by excitatory afferents (Snyder et al., 2005). 
DAGLs accumulate at the neck of dendritic spines (Yoshida et al., 2006) where they are anchored 
by homer-1 and -2 family scaffolding proteins (Jung et al., 2007; Roloff et al., 2010). Notably, 
soluble Aβ oligomers induce the disassembly of homer-containing postsynaptic clusters (Roselli et 
al., 2009), thus potentially affecting the subcellular recruitment and signalling competence of 
DAGLs. These changes, together with increased DAGL activity upon Aβ-induced Ca2+ overload in 
neurons (provided that DAGLs are Ca2+-dependent (Bisogno et al., 2003)) and increased DAGL 
expression in microglia can significantly increase 2-AG availability in AD. 
AD has long been viewed as a disease stemming from neuronal hypofunction. This concept has 
recently been challenged by demonstrating that neurons near Aβ-containing plaques are focally 
‘hyperactive’, whilst others away from plaque-laden areas are silent (Busche et al., 2008). Neuronal 
hyperactivity is suggested to be due to a relative decrease in synaptic inhibition (Busche et al., 
2008). We find that the molecular composition of 2-AG signalling networks undergoes profound 
modifications around Aβ-containing senile plaques in the human hippocampus in AD. These 
observations led us to hypothesize that if the efficacy of retrograde signalling is increased in AD 
then it may directly contribute to synapse silencing. 
Our proof-of-concept neurophysiology experiments support this notion by showing a significant 
increase in DSI duration, thus suggesting that 2-AG-mediated feedback is a particular mechanism 
through which Aβ could disrupt inhibitory neurotransmission at GABAergic synapses. Functionally, 
DSI may serve to lengthen the firing duration of postsynaptic neurons by abating inhibitory inputs 
during periods of high excitatory activity. By prolonging DSI decay, Aβ can further extend the 
excitatory neurons’ firing periods, thus increasing overall network excitability. Previously, we have 
reported (Minkeviciene et al., 2009) that Aβ induces neuronal hyperexcitability by significantly 
depolarizing the resting membrane potential of excitatory neurons and lowering their response 
threshold. This effect is exerted without a requirement for preceding postsynaptic activation, as in 
the case with DSI. Thus, prolonging DSI through decay by reorganizing endocannabinoid signalling 
is potentially one key mechanism by which Aβ can modulate neuronal network excitability. Since 
inhibitory synapses are more resistant to AD than excitatory ones (Bell et al., 2006), prolonged DSI 
may destabilize hippocampal networks by shifting the net balance of inhibition and excitation in 
favour of excitation. Thus, decreased inhibitory neurotransmission will ultimately manifest in 
‘hyperactivity’ (Busche et al., 2008; Minkeviciene et al., 2009), which may explain the increased 
incidence of unprovoked epileptic seizures in Alzheimer’s patients (Hauser et al., 1986). 
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17 
Synaptic impairment is a central feature of AD-related cognitive decline. It is widely accepted that 
Aβ preferentially target excitatory synapses (Lacor et al., 2004). CB1Rs are expressed by both 
inhibitory interneurons and pyramidal cells with inhibitory terminals containing exceptionally high 
levels of this receptor (Kawamura et al., 2006). Our finding that CB1R levels fail to correlate with 
presynaptic markers suggests that the molecular changes in 2-AG signaling networks we have 
identified are unlikely to reflect the overall rate of synaptic demise in moderate or severe AD. Even if 
Aβ induces opposing – and proportional – changes in CB1R expression (that is, to increase CB1R 
content in inhibitory but decrease CB1R levels in excitatory terminals), the neurochemical 
homogeneity of perisomatic inhibitory synapses under endocannabinoid control (Kano et al., 2009) 
suggest that Aβ can impose functional modifications to endocannabinoid signaling at specific 
synapse populations. This concept is supported by the fact that acute Aβ superfusion is unlikely to 
eliminate hippocampal synapses within the brief superfusion period used when studying the decay 
of DSI. Therefore, we propose that endocannabinoid signalling is a key neuromodulatory 
homeostatic system mediating adaptive responses to neurotoxic insults (Bisogno and Di Marzo 
2008) and defining the dynamics of presynaptic neurotransmitter release under disease conditions. 
2-AG signalling in microglia: the good, the bad or the ugly? 
Microglia are central to AD pathogenesis since their activation state determines whether they are 
beneficial by phagocytosing cell debris or elicit neuronal injury by releasing proinflammatory 
cytokines. Migrating microglia express CB2Rs whose activation suppresses proinflammatory 
cytokine production (Klegeris et al., 2003). Once activated, microglia downregulate CB2Rs, as seen 
upon WNT-3A challenge, to increase cytokine production. Microglia continuously monitor the 
functional state of synapses via the dynamic motility of their processes. Disrupting neuron-glia 
communication (also including astrocyes) (Rodriguez et al., 2009) will therefore culminate in the 
loss of glial homeostatic control, and facilitate the onset of synaptic deficit. Thus, altered 2-AG 
signalling in activated microglia can have serious consequences in AD, particularly since a 2-AG 
‘overflow’ may be viewed as a volumetric insult indiscriminately affecting synapse populations and 
assemblies of neurons. Overall, pathogenic modifications to 2-AG metabolism in microglia can 
exacerbate synaptic impairment in AD. 
2-AG hydrolysis by ABHD6 and MGL in Alzheimer’s disease 
ABHD6 and MGL terminate surplus 2-AG to maintain temporally coordinated retrograde signalling 
(Marrs et al., 2010; Dinh et al., 2002). AD pathology will ultimately modify 2-AG signalling if it either 
impacts the recruitment of ABHD6 and/or MGL to signalling positions or compromises their 
enzymatic activity. We find that AT8+ neurons cease ABHD6 expression, suggesting impaired 
postsynaptic 2-AG degradation when the cytoskeletal integrity of neurons becomes compromised. 
The loss of ABHD6 recruitment may be pathophysiologically significant since it could alter the 
balance of postsynaptic 2-AG synthesis and degradation such that 2-AG could continuously ‘leak’ 
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18 
out of subsynaptic dendrites. Thus, the lack of ABHD6-mediated ligand degradation may impair the 
temporal precision of retrograde signalling. 
MGL-dependent 2-AG degradation requires MGL’s recruitment as a dimer to the internal leaflet of 
the plasmalemma (Labar et al., 2010). Our findings reveal that MGL’s association to the 
plasmalemma is particularly hindered in AD brains. Instead, MGL is sequestered in the cytosol, 
which we consider incompetent to degrade 2-AG targeting transmembrane receptors and 
participating in retrograde signalling. We propose that diminished association of MGL to the 
plasmalemma may be due to intracellular acidosis or membrane damage through lipid peroxidation 
(Querfurth and LaFerla 2010). Nevertheless, our biochemical data suggest the existence of 
compensatory mechanisms since the contribution of JZL184/URB602-insensitive 2-AG degrading 
enzymes is markedly increased in AD, compatible with our observation of increased ABDH6 
expression in microglia and/or astrocytes. We also find that Aβ is central to regulating both the 
subcellular localization and activity of MGL. The physiological significance of this interaction may be 
increased intracellular 2-AG degradation preventing receptor-independent antioxidant actions of 2-
AG (Bisogno and Di Marzo 2008), thus predisposing neurons to Aβ-induced oxidative damage. 
Previous studies demonstrate that cannabinoids may rescue neurons under AD-like conditions by 
suppressing pro-inflammatory microglia activity (Ramirez et al., 2005). Our present results uncover 
novel mechanistic insights in neuronal (synaptic) 2-AG signalling, as well as 2-AG-mediated 
neuron-glia interactions. We suggest that reduced pre- as well as postsynaptic 2-AG degradation 
coincident with increased and ectopic 2-AG synthesis can disrupt the temporal and spatial control of 
retrograde signalling, and - consequently - aggravate synapse impairment in AD. Therefore, 
endocannabinoid signalling networks may represent novel targets to reinstate the precision of 
synaptic communication under neurodegenerative conditions associated with cognitive deficit. 
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Legends to Figures 
Figure 1 Changes in DAGL and MGL protein expression in human hippocampus coincide 
with Alzheimer’s progression. (A) Representative images of molecular targets 
resolved by Western blotting. Data (in kDa) indicate the calculated molecular weights 
of the molecules of interest. Solid and open arrowheads identify MGL’s 33 kDa and 30 
kDa, respectively. Calculated molecular weights corresponded with those measured in 
particular experiments in all cases. We did not observe modifications to the molecular 
weights of any of the targets analyzed (otherwise represented as vertical size shifts) 
when comparing data from control, moderate or severe Alzheimer’s (B2-4 and B6, 
respectively) cohorts. Normalized expression (average of controls = 1.0) of CB1Rs (B), 
DAGLα (C; +p < 0.1), DAGLβ (C1), ABHD6 (E), 30 kDa (F) and 33 kDa (F1) isoforms of 
MGL. Individual data points and their colour coding correspond to post-mortem cases 
listed in Table S1. β-actin was used as loading control to normalize our data (Fig. 
S1B,B1). Horizontal lines represent the mean value of particular patient cohorts. (D) 
DAGLα and DAGLβ levels correlated positively in controls (not marked), lost 
correlation in B2-4, while exhibited a strong negative expressional relationship in B6. 
(red dashed line; G) MGL isoform expression positively correlates during AD 
progression. *p < 0.05 (Student’s t-test). 
Figure 2 CB1R distribution in aged human hippocampus and in Alzheimer’s. (A) Schema of 
the human hippocampal formation. Open rectangles identify the general location of 
images in (B) and (E). (B) CB1R immunoreactivity overlaps with synaptophysin+ nerve 
terminals targeting the perisomatic region (C) as well as apical dendrites (D) of CA1 
pyramidal neurons. High-resolution microscopy reveals CB1R+/synaptophysin+ 
terminals (arrowheads) around pyramidal cell perikarya (C-C3) and dendrites (D-D3). 
Note the mutually exclusive localization of CB1Rs and MAP2+ dendrites. Dashed lines 
encircle neuronal somata (C) and dendrite (D). Asterisks in (C) are overlain on 
neuronal nuclei. (E) CB1R+ afferents engulf cells in the granular layer abundantly 
immunoreactive for Aβ(17-24), likely localizing intracellular APP, as well as Aβ(17-24)+ 
senile plaque (open rectangle). (E1-E3) The density of CB1R+ axons and synapses 
appear unchanged in the proximity of senile plaques. Instead, CB1R+ processes 
appear to accumulate locally around, and even penetrate senile plaques (arrows). 
Abbreviations: CA, Ammon’s horn; DF, dentate fascia; sub., subiculum. Scale bars = 
20 µm (B,E,E3), 12 µm (C3,), 4 µm (D3). 
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Figure 3 Differential DAGLα and DAGLβ expression and localization in aged human 
hippocampus and in Alzheimer’s. (A) Schematic overview of hippocampal subfields 
with open rectangles identifying the localization of dendritic fields shown in (B,F). (B) 
MAP2+ dendritic shafts (arrows) are embedded in a fine meshwork of DAGLα+ and/or 
DAGLβ+ puncta, with the density of DAGLα immunoreactivity surpassing that of 
DAGLβ in the aged human hippocampus (control). (C) High-resolution imaging reveals 
co-existence of DAGLα and DAGLβ (arrowheads) in MAP2+ compartments. (D) Three-
dimensional reconstruction of a MAP2+ pyramidal dendrite verifies the postsynaptic 
recruitment of DAGLs, and high-power rendering positions both DAGLα and DAGLβ in 
the dendritic spine neck (D1). (E) Pearson’s correlation coefficient suggests moderate 
positive correlation between the fluorescence maxima of DAGLα and DAGLβ. (E1,E2) 
Area occupancy and co-localization coefficients for DAGLα and DAGLβ 
immunoreactivities verify the greater abundance of DAGLα, and reveal differences in 
their probability of co-localization, respectively. Data were expressed as means ± 
s.e.m. (F) The distribution of DAGLα does not change around Aβ(17-24)+ senile 
plaques in AD. However, DAGLβ immunoreactivity focally concentrates in periplaque 
regions (F1) in small-diameter cell-like structures (arrowheads, F1) but not CB1R+ 
processes (open arrows). Such DAGLβ+ cells closely appose (arrowheads, F2) CB1R+ 
axon terminals (arrows, F2), and, based on their IBA-1 expression, were identified as 
activated microglia in Alzheimer’s brains (arrows; G-G2). Asterisks in G-G2 pinpoint the 
soma of the microglial cell. Abbreviations: DF, dentate fascia; sub., subiculum. Scale 
bars = 40 µm (B2), 10 µm (F,F1), 4 µm (C3,F2,G3). 
Figure 4 Pathological alterations in the cellular distribution of serine hydrolase ABHD6 in 
Alzheimer’s hippocampus. (A-A2) ABHD6 is distributed along the somatodendritic 
axis of hippocampal pyramidal cells in aged (control) human hippocampus. (B) We find 
ABHD6 expression in small, multipolar MAP2- cells, presumed microglia, coincident 
with a decrease in dendrite labelling in neurons (asterisk) in Braak 2-4 disease. (B1,B2) 
This AD-related ABHD6 distribution pattern is exacerbated in Braak 6 with ABHD6 
immunoreactivity localized to small calibre, IBA1+ microglia processes. (C,C1) ABHD6 
is excluded from AT8+ neurons (asterisk), though retained in proximal dendrites of cells 
without appreciable neurofibrillary pathology. (D-D3) ABHD6+/IBA1+ microglia populate 
plaque-laden regions in severe AD. Open and solid arrowheads point throughout to 
ABHD6+ dendrites and microglia-like cells, respectively. Scale bars = 12 µm. 
Figure 5 MGL in the aged human hippocampus. (A) Schematic overview of the human 
hippocampal formation with open rectangles identifying the surface areas presented in 
panels (B), (C) and (H). (B,B1) MGL immunoreactivity (open arrowheads) is confined 
not only to the somata of granule cells but also to ramifying astroglia-like cells in the 
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dentate gyrus (open arrowheads). (C) CB1R+ afferents target MGL+ CA1 pyramidal 
cells. Open rectangles point out the location of insets in (D,E). (D-D3) MGL decorates 
the cytoplasm of pyramidal cells. (E-E3) MGL accumulates in presynapses as revealed 
by the presence of MGL+/CB1Rs+ terminals on pyramidal cell dendrites (arrows). 
Dashed lines encircle neuronal somata (D) and dendrite (E). (F,F1) Three-dimensional 
reconstruction of a dendrite segment confirms that MGL (open arrowheads) is 
excluded from dendrites/dendritic spines, as well as astroglial end-feet. (G) Pearson’s 
correlation coefficient of MGL and CB1R fluorescence intensities. (G1) Relative area 
coverage of MGL+ and CB1R+ structures over pyramidal cell dendrites in the stratum 
radiatum. (G2) Co-localization coefficients for MGL and CB1R immunoreactivities reveal 
differential probabilities for these molecular targets to coexist. (H) MGL accumulates on 
the membrane surface of a subset of astroglia in aged human brain. Scale bars = 80 
µm (B1), 20 µm (C,H), 6 µm (D3,E3). 
Figure 6 MGL localization in Alzheimer hippocampus. (A,A1) MGL isoform expression 
exhibits positive correlation with AD progression. (A2) This relationship is not biased by 
the post-mortem delay (h). (B,B1) IBA-1+ microglia cells (arrowheads) recruited to 
senile amyloid plaques express MGL in AD. (C-C2) MGL expression is retained at 
reduced levels in neurons with moderate (C, **) and severe (C1,C2, *) neurofibrillary 
pathology. (D) Quantitative immunofluorescence analysis of MGL levels in neurons 
with (AT8+) or without (AT8+) hyperphosphorylated tau. Symbols in brackets denote 
group means. Abbreviation: g.s.u., grey-scale unit. ***p < 0.001 (Student’s t-test). 
Scale bars = 12 µm (C’-C2’’), 8 µm (B,B1). 
Figure 7 2-AG degradation in Alzheimer’s and its Aβ(1-40)-induced activation. (A) Pro-
inflammatory transformation by WNT-3A (300 ng/ml, 6h) (Halleskog et al., 2011) down-
regulates MGL expression in primary mouse microglia. Interleukin-6 and tumor 
necrosis factor (TNF) were used as positive (internal) controls. (B) 2-AG is differentially 
metabolized in AD frontal cortex: membrane-associated 2-AG-degrading enzymatic 
activity is decreased, while cytosolic 2-AG-degrading activity is significantly increased, 
relative to controls. (C) Membrane-associated MGL activity accounts for ~60% of total 
2-AG hydrolysis activity as revealed by JZL184 application (see also Fig. S8B,B1) in 
membrane samples prepared from control human specimens. Note that JZL184-
sensitive 2-AG degrading activities are selectively lost in AD. (C1) 2-AG hydrolysis 
activity significantly increases in cytosol fractions from AD brains, as compared to 
controls. JZL184 partially reduces 2-AG degradation in cytosolic fractions prepared 
from control brains and eliminates disease-associated enhancement of 2-AG 
catabolism in AD brains. (D) FAAH does not contribute to 2-AG degradation at either 
subcellular fraction as tested by URB597. (E) Pre-incubation of cortical tissue 
homogenates from control subjects with Aβ1-40 significantly increases both 
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membrane-bound and cytosolic 2-AG metabolism. (E1) Aβ1-40 induces 2-AG 
degrading enzymatic activity in a dose-dependent manner. *p < 0.05, **p < 0.01 vs. 
controls; #p < 0.05, ## p < 0.01 vs. non-treated samples. Abbreviations: n/a, not 
analyzed; n.s., not significant; N.T., non-treated. 
Figure 8 Aβ(1-42) triggers subcellular redistribution of 2-AG signalling networks and 
prolongs DSI. (A-A3) Representative images of molecular targets resolved by Western 
blotting. Cytosol and membrane fractions are from the same sample to establish the 
impact of Aβ(1-42) on subcellular receptor and enzyme recruitment, as compared to 
controls in artificial cerebrospinal fluid (aCSF). Aβ(1-42) exposure significantly alters 
intracellular vs. cell-surface concentrations of CB1Rs (A1), DAGLα (A2) and MGL (A3). 
Data on MGL shows cumulative changes in this enzyme’s 33 and 30 kDa isoforms. (B) 
Representative experiment showing DSI induced by a step depolarization of a CA1 
pyramidal neuron. (B1) Postsynaptic depolarization-induced reduction of spontaneous 
IPSCs (downward deflection from baseline) is prolonged by bath-applied Aβ(1-42) (1 
µM). (B2) Summary of DSI magnitude and kinetics measured in control (open circles; n 
= 10 cells) or in the presence of Aβ(1-42) (solid circles; n = 11). AM251 (1 µM) 
abolishes DSI in control (C), as well as Aβ(1-42)-superfused CA1 pyramidal neurons 
(D,D1). **p < 0.01 (Student’s t-test). Data were expressed as means ± s.e.m. 
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Supplementary text: Materials & methods 
Human tissues and ethical approval of the studies. Hippocampal tissues were obtained from 
Alzheimer’s (AD) patients and age-matched controls (without clinical signs of neuropsychiatric 
disease) at the London Neurodegenerative Diseases Brain Bank. Local ethical committee approval 
(#231/2001) and informed consent from the next of kin have been obtained to harvest post-mortem 
tissues (Table S1). All patient material was coded to ensure anonymity throughout tissue processing. 
Classification of Aβ plaque burden (Fig. S1A) and tau pathology (Table S1) was performed as 
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Aβ plaque burden, qualifying for ‘low’, ‘intermediate’, and ‘high’ likelihood of AD/dementia according to 
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assigned to this study (Table S1) and grouped as: controls (n = 7, mean age of death: 74.42 ± 6.11 
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moderate AD from patients with Braak stage III (n = 4, mean age of death: 91.75 ± 5.7 years) and IV 
(n = 5, mean age of death: 84.00 ± 3.33 years); and severe AD with patients exhibiting pathological 
signs of Braak stage VI disease (n = 9, mean age of death: 82.00 ± 2.69 years). 
An independent cohort of AD and age-matched control cases was made available by the London 
Neurodegenerative Diseases Brain Bank for use in MGL and FAAH enzyme activity measurements: 
controls (n = 18, mean age of death:  71.8 ± 2.6 years, mean post-mortem delay (h): 38.7 ± 4.7h), AD 
patient pool (n = 18; mean age of death: 77.4 ± 2.2 years; mean post-mortem delay (h): 33.3 ± 5.3), 
matched for sex (13 females/5 males). 
Ethical approval of studies in rodents. Experimental procedures on mice were approved by the 
Home Office of the United Kingdom and conformed to the European Communities Council Directive 
#86/609/EEC. Particular care was taken to minimize the number of animals and their suffering 
throughout the experiments. 
Aβ measurements. Soluble and detergent-resistant/insoluble Aβ fractions were separated by 
centrifugation (14,000g for 30 min) as described (Walsh et al., 2002). Insoluble Aβ was extracted from 
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 3 
the pellet using 5M guanidine followed by sandwich ELISA detection of Aβ(1-42) (Invitrogen). Aβ(1-
42) concentrations were expressed as pg/µg protein (Fig. S1A). 
Immunohistochemistry. Multiple immunofluorescence histochemistry was performed on 7 µm-thick 
human temporal lobe sections containing the hippocampal formation cut from paraffin-embedded 
blocks on a sliding microtome, and mounted onto glass slides coated with 3-
aminopropyltriethoxysilane (Sigma). Sections were de-waxed in xylene, rinsed in ethanol, and 
endogenous peroxidase activity was blocked by 1% H2O2 in 100% methanol (30 min). Antigen 
retrieval was routinely carried out by incubating sections in 5% urea in 0.1M Tris-HCl (pH 9.5) and 
microwaving (800W, 8 min) followed by incubation in ice-cold NaHBO4 (0.5%, in PB for 5-10 min). 
Non-specific immunoreactivity was suppressed by incubating our specimens in a cocktail of 10% 
normal donkey serum (NDS; Jackson), 5% BSA (Sigma) and 0.3% Triton X-100 (Sigma) in PB. 
Sections were exposed to combinations of primary antibodies (Table S2) in PB also containing 1% 
NDS and 0.2% Triton X-100 for 16-72 h at 4 
o
C. After extensive rinsing in PB, immunoreactivities 
were revealed by carbocyanine (Cy2) 2, 3 or 5-tagged secondary antibodies raised in donkey (1:200 
[Jackson], 2 h at 22-24 
o
C). Tissues were routinely counterstained by Hoechst 35,528 nuclear dye 
(Sigma). Lipofuscin autofluorescence was blocked by applying Sudan Black-B (1%, dissolved in 70% 
ethanol; Fig. S3) (Schnell et al., 1999). Sections were coverslipped by Aquamount (DAKO). 
Laser-scanning microscopy. Sections were inspected and images were acquired on a 710LSM 
confocal laser-scanning microscope (Zeiss). Emission spectra for each dye were limited as follows: 
Hoechst (420-485 nm), Cy2 (505-530 nm), Cy3 (560-610 nm), and Cy5 (640-720 nm). Image surveys 
were generated using the tile scan function with optical zoom ranging from 0.6x to 1.5x at 10x primary 
magnification (objective: EC Plan-Neofluar 10x/0.30). Co-localization was defined as immunosignals 
being present without physical signal separation in ≤ 1.0-µm optical slices at 40x (Plan-Neofluar 
40x/1.30) or 63x (Plan-Apochromat 63x/1.40) primary magnification (Mulder et al., 2009; Keimpema 
et al., 2010). The co-localization utility of the ZEN2009 software package was used (Keimpema et al., 
2010) to determine i) the relative area occupancy for each fluorochrome, defined as the density of 
fluorescence pixels normalized to a 1 µm
2
 surface area, ii) the co-localization coefficient of CB1R, 
DAGLα, DAGLβ and MGL immunoreactivities along apical dendrites of hippocampal pyramidal 
neurons, expressed as the relative number of co-localizing pixels in one channel as compared to the 
total number of pixels above threshold in another channel, and iii) Pearson’s correlation coefficient 
defining the intensity distribution within co-localizing regions (ranging from -1 to +1 with 0 indicating no 
correlation). Images were processed using the ZEN2009 software (Zeiss). Multi-panel figures were 
assembled in CorelDraw X5 (Corel Corp.). 
Autofluorescence background artifacts and post-mortem delay-related staining variations may 
introduce bias in quantitative immunohistochemical analysis. Therefore, we have routinely quenched 
tissue autofluorescence (lipofuscin, myelin) by applying Sudan Black-B. By means of spectral 
unmixing (Halleskog et al., 2011) we have verified that Sudan Black-B quenched ≥ 90% of non-
specific background fluorescence in individual emission spectra used for quantitative analysis (Fig. 
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 4 
S3A,B and C1-C3). Thus, we sampled specific immunosignals restricted to Cy2-Cy5 emitting 
fluorophores (Fig. S3C) during quantitative analyses. 
Quantitative subcellular immunohistochemistry was performed on specimens stained simultaneously. 
Differences in post-mortem delay are unlikely to affect the histochemical outcome (considering that 
post-mortem delay (h) does not significantly alter protein concentrations of our molecular targets; Fig. 
S4A-E). Nevertheless, we controlled the sampling errors in our quantification protocols by minimizing 
the population spread in the fluorescence intensity spectra of the tissue samples analyzed (Fig. S6A3-
C) (Halleskog et al., 2011). Fluorescence intensities at relevant excitation/emission wavelengths were 
simultaneously adjusted such that random over- or under-sampling of fluorescently-labelled structures 
was eliminated (Fig. S6A3-C). A relationship between MGL and AT8 immunofluorescence intensities 
was established after manually delineating individual hippocampal principal cells and calculating 
integrated fluorescence intensity values by an experimenter blind to the case conditions. This 
approach effectively minimized data spread and sampling error. 
Three-dimensional reconstruction. Serial orthogonal images (z-stacks) of select dendrite segments 
in CA1 stratum radiatum were captured at 40x primary objective magnification (EC Plan-Neofluar 
40x/1.3 oil, 2x optical zoom, pinhole: 20 µm, 1024 x 1024 pixel resolution) resulting in image stacks 
containing 32 - 36 z levels scaled as x = 0.104 µm, y = 0.104 µm and z = 0.324 µm. Single channels 
in individual images were exported as grey-scaled graphic images (*.tiff), and imported into BioVis3D 
reconstruction package (Montevideo, Uruguay) using original scale settings to retain the correct size 
and position of each pixel in a given z-stack. First, the contour of a select dendrite was established by 
using serial MAP2
+
 images. Dendrites oriented in an acute angle were preferred since their shaft 
could precisely be followed through the entire series of images, and all spine-like structures could be 
defined. The outline of a dendrite cumulated from the entire image stack was then used to render the 
three-dimensional model of a single dendrite fragment. Spines that were outlined but not connected to 
the selected dendritic shaft were discarded. Next, images in separate LSM channels representing 
DAGLα, DAGLβ, MGL or GFAP were loaded into the reconstruction package to define the 
immunoreactivity for each protein in the close proximity of the selected dendrite through each z level. 
Individual outlines were overlaid and rendered simultaneously to produce a detailed three-
dimensional structural model. Subsequently, protein distribution inside a dendrite segment and 
dendritic spines was visualized by using a transparency utility of BioVis3D. 
Western blotting. Blocks of human hippocampi were homogenized in TNE buffer containing 0.5% 
Triton X-100 (Sigma), 1% octyl-β-D-glucopyranoside (Calbiochem), 5 mM NaF, 100 µM Na3VO4 and a 
cocktail of protease inhibitors (Complete
TM
, Roche) by using an Ultra Turrax® tube drive (IKA). Whole 
mouse hippocampi were homogenized in TNE buffer containing 1% Triton X-100 (Sigma), 5 mM NaF, 
100 µM Na3VO4 and a cocktail of protease inhibitors (Complete
TM
). 
Tissues from acute hippocampal slices were processed by ultrasonication in TNE lysis buffer also 
containing 0.32 M sucrose, 1% octyl-β-D-glucopyranoside, 5 mM NaF, 100 µM Na3VO4, and protease 
inhibitors (Paratcha et al., 2003). Cell debris and nuclei were removed by centrifugation (800g, 10 min 
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 5 
at 4 
o
C). Membrane and cytosol fractions were separated using the same buffer by centrifugation at 
14,000g for 30 min at 4 
o
C. Membrane fractions were washed in TNE buffer containing 5mM NaF, 
100µM Na3VO4 and protease inhibitors, and lysed in TNE buffer supplemented with 0.5% Triton X-
100, 1% octyl-β-D-glucopyranoside, 5 mM NaF, 100 µM Na3VO4, and protease inhibitors 
(Complete
TM
) for 90 min. Protein concentrations were determined by Bradford’s colorimetric method 
(Bradford 1976). 
Samples were diluted to a final protein concentration of 2 µg/µl, denatured in 5x Laemmli buffer, and 
analyzed by SDS-PAGE on 8% or 10% resolving gels (Berghuis et al., 2004). After transferring onto 
Immobilon-FL polyvinylidene difluoride membranes (Millipore), protein samples on membranes were 
blocked in Odyssey blocking buffer (LiCor Biosciences; 1h) and exposed to primary antibodies (Table 
S2; Fig. S2) overnight at 4 
o
C. Appropriate combinations of IRDye-800CW and IRDye-680-conjugated 
secondary antibodies were used for signal detection (LiCor Biosciences; from goat or rabbit hosts; 
1:10,000, 2h). Image acquisition and analysis were performed on a LiCor Odyssey IR imager. β-III-
tubulin (1:4,000; Promega) and β-actin (1:10,000; Sigma) served as loading controls. 
Dot blot. A Bio-dot microfiltration blotting device (Bio-Rad) was used. Samples (25 µg protein/well) 
were blotted onto Hybond-P PVDF protein membranes (GE Healthcare), air dried, washed in 50 mM 
Tris HCl buffer (pH 7.4) containing 0.1% Tween-20 (TT solution), blocked in 5% BSA in TT solution, 
and exposed to primary antibodies overnight at 4 
o
C. Specificity of the polyclonal anti-TRPV1 antibody 
was verified in TRPV1
-/-
 mice (V. Di Marzo, pe sonal communication) (Cristino et al., 2008). Tissues 
from adult mouse cerebellum were used as positive control (data not shown) (Cristino et al., 2008). 
The enhanced chemiluminescence method was used for signal amplification and detection (Bio-Rad 
Chemidoc XRS
+
). β-Actin was used as loading control. 
Membrane preparation for [
3
H]resiniferatoxin binding. Membrane preparation was carried out 
according to previously published protocols (Hartshorne and Catterall 1984) with slight modifications. 
Wild-type (WT, n = 4, 3 months of age) and age-matched TRPV1
-/-
 mice (n = 4; kindly provided by A. 
Avelino) (Caterina et al., 2000), as well as Wistar rats (Charles River, Barcelona, Spain; n = 4 at 3 
months of age) were decapitated under halothane anaesthesia. Whole brains were rapidly removed, 
striata were dissected out, and homogenized in ice-cold sucrose solution [0.32 M sucrose, 10 mM 
HEPES, 1 mM EDTA, protease inhibitor cocktail (Sigma), pH = 7.4]. Whole brain and striatal 
homogenates were centrifuged at 700g/10 min and 3,000g/5 min, respectively. Pellets were 
discarded. Supernatants were centrifuged at 28,000g for 40 min and the resultant pellets were re-
suspended in 20 ml of ice-cold washing solution [Trish/HCl (50 mM), MgCl2 (3 mM), CaCl2 (2.5 µM), 
and protease inhibitor cocktail, pH 8.2]. After another washing/centrifugation (28,000g/40 min) step, 
the final pellet was stored at -20 ºC until analysis. 
Optimization of [
3
H]resiniferatoxin binding. First, we determined [
3
H]resiniferatoxin ([
3
H]RTX) 
binding by establishing saturation curves in WT and TRPV1
-/-
 membranes (Fig. S5G,G1), in the 
presence of (E)-capsaicin (1 µM, Tocris; dissolved in DMSO whose final concentration was 0.1% in all 
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 6 
experiments), a potent and selective TRPV1 agonist or its inactive enantiomer, (Z)-capsaicin (1 µM; 
Tocris). Binding assays were performed in triplicate in conical 96-well plates. The reaction mixture 
consisted of 100 µg protein sample (50 µl of 2mg/ml homogenate), capsaicin solution or vehicle (100 
µl), [
3
H]RTX (PerkinElmer, specific activity: 40.5 µCi/mmol) as 100 µl solution at concentrations 
ranging from 20 pM to 1.5 nM. Protein samples were substituted by assay solution in separate control 
experiments to measure radioactivity retention by absorption filters in the presence or absence of cold 
ligands. The assay solution contained: Trish/HCl (50 mM), MgCl2 (1 mM), MgSO4 (2 mM), CaCl2 (2.5 
µM), and protease inhibitor cocktail (pH 7.4). We omitted BSA from the assay solution since, in pilot 
experiments, we failed to find [
3
H]RTX binding displaced by (E)-capsaicin when BSA (1.6 mg/ml) was 
present (data not shown). Samples were incubated at 37 ºC for 1h. After incubation, samples were 
vacuum-filtered and washed on GF/B filters (Whatman) with ice-cold Trish/HCl solution (50 mM). 
Filters were harvested into 20 ml scintillation tubes containing 3 ml scintillation liquid (Aquasafe, 
Zinsser), and assayed for radioactivity three times in three consecutive days. Radioactivity was 
converted to fmol [
3
H]RTX/mg protein binding values after subtracting non-specific retention values 
from filters without protein samples. 
Optimal [
3
H]RTX saturation was obtained by subtracting the average total binding values from TRPV1
-
/-
 from corresponding values in WTs (illustrated in red, Fig. S5G1). (E)-Capsaicin failed to completely 
displace [
3
H]RTX binding in WTs membranes (in blue, Fig. S5G1) as explained by the phenomenon 
that lipophilic unlabeled (‘cold’) ligands can increase non-specific binding. That is, both (E)-capsaicin 
and (Z)-capsaicin in KO membranes as well as (Z)-capsaicin in WT membranes augmented total 
(non-specific) binding. This increase was 19.1 ± 4.4% by (E)-capsaicin in WT membranes at a 
[
3
H]RTX concentration of 1.5 nM. This phenomenon is at least partly responsible for the inability of 
(E)-capsaicin to produce an ‘ideal’ [
3
H]RTX saturation curve in WTs. Therefore, we used a 
normalizing factor of 0.84. 
[
3
H]resiniferatoxin binding in human hippocampus. Specific [
3
H]RTX binding was determined in 
post-mortem hippocampi (100 µg protein/sample) from moderate AD (B2-4; n = 7), severe AD (B6; n 
= 5) and age-matched controls (n = 5) using a [
3
H]RTX concentration of 1.5 nM. Rat striatal 
synaptosomes (100 µg protein/well, 4 preparations in triplicate), in which postsynaptic TRPV1s have 
been identified earlier (Maccarrone et al., 2008), were used as positive control (Fig. S5G2). Data were 
expressed as specific [
3
H]RTX binding (fmol [
3
H]RTX/mg protein). 
Acute brain slice preparation and electrophysiology. Sagittal brain slices (300 µm) were prepared 
from 14- or 16-day-old C57Bl/6N mice. Animals were killed by decapitation. Whole brains were 
removed, placed in ice-cold cutting solution containing (mM):140 K-gluconate, 15 Na-gluconate, 0.2 
EGTA, 4 NaCl, 10 HEPES, and sectioned on a Leica VT1000S vibratome. Brains slices were acutely 
equilibrated for 1h in extracellular solution containing (mM): 126 NaCl, 3.5 KCl, 2 CaCl2, 1.3 MgCl2, 26 
NaHCO3, 1.2 NaH2PO4 and 10 glucose, at room temperature. In biochemical experiments, 
hippocampal slices were transferred to a submerged chamber containing oxygenated (95% O2/5% 
CO2) extracellular solution with/without Aβ(1-42) (provided by Drs. B. Penke and L. Fülöp, University 
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 7 
of Szeged, Hungary). Aβ(1-42), containing a mixture of oligomers and protofibrils (Minkeviciene et al., 
2009), was directly dissolved in extracellular solution at a final concentration of 1 µM. Slices were 
snap-frozen in liquid N2 after 1h Aβ(1-42) exposure and stored at -80 
o
C until processing. 
CA1 pyramidal cells were visualized by infrared differential interference contrast microscopy (Olympus 
BX51) and whole-cell recordings were performed at 22-24 
o
C. Patch electrodes had 4-8 MΩ 
resistance when filled with intracellular solution consisting of (mM): 125 K-gluconate, 20 KCl, 4 ATP-
Mg, 10 Na-phosphocreatine, 0.3 GTP and 10 HEPES (pH 7.3). Spontaneous IPSCs (sIPSCs) were 
recorded on a Multiclamp 700A amplifier (Axon Instruments), sampled at 20 µs intervals, filtered at 2 
kHz and stored for off-line analysis using Igor Pro 6.0 software (Wavemetrix). Recordings were 
performed in the presence of CNQX (20 µM, Tocris), D-AP5 (50 µM, Tocris) to eliminate ionotropic 
glutamatergic neurotransmission, as well as carbamoylcholine chloride (5 µM [carbachol], Tocris). 
Access resistance was not compensated but frequently monitored and cells showing large deviations 
(>25%) were excluded from analysis. 
Aβ(1-42) effects on depolarization-induced suppression of inhibition (DSI) were determined by pre-
incubating sister (consecutive) slices for 1h in a bath solution also containing 1 µM Aβ(1-42), and by 
alternating recordings between control vs. Aβ(1-42)-exposed slices to eliminate methodological 
artifacts (Minkeviciene et al., 2009). We refrained from using ionic (buffer) conditions (e.g. CsCl2) or 
inhibitor(s) that may affect voltage-gated channel conductances to minimize unwanted interference 
with Aβ(1-42) actions and, consequently, physiological outcome. 
sIPSCs were measured in voltage clamp mode, at a holding potential of -80 mV. DSI was elicited by 
step depolarization to 0 mV for 1s. A 15s period prior to the depolarization step served as control. DSI 
was calculated over a 50s period starting 1s after the depolarizing pulse’s end (the 1s period 
eliminated the latency period of DSI (Wilson and Nicoll 2001) from our analysis). Mean sIPSC transfer 
charge was calculated over 5s time bins (Makara et al., 2007). AM251 (Tocris) was applied at a final 
concentration of 1µM. DSI was calculated based on data from n = 1-4 DSI/condition/cell. The recovery 
time course of DSI (Straiker et al., 2009) was fitted with a single-exponential decay curve (GraFit 5.0; 
Erithacus Software). 
Legends to Supplementary Tables & Figures 
Table S1 Characteristics of the control and Alzheimer’s subjects. Abbreviations: BW, brain 
weight; h, hour; IH, sample processed for immunohistochemistry; PMD, post-mortem 
delay; WB, sample analyzed by Western blotting; y, year. 
Table S2 List of markers used for immunofluorescence labelling. Panels of antibodies applied 
to study the molecular composition (A) and cell-type-specificity (A1) of 2-AG signalling in 
human and mouse brain. Staining methods (Riedel et al., 2002; Harkany et al., 2003) and 
antibody specificities were described in detail elsewhere unless otherwise stated. Table 
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 8 
(A) and (A1) list antibodies against molecular constituents of 2-AG and AEA signalling 
networks (Katona et al., 1999; Katona et al., 2001; Harkany et al., 2003; Okamoto et al., 
2004; Van Sickle et al., 2005; Yoshida et al., 2006; Berghuis et al., 2007; Rimmerman et 
al., 2008; Cristino et al., 2008; Straiker et al., 2009; Marrs et al., 2010) and neuronal 
identity markers (Binder et al., 1986; Braak et al., 1994; Thal et al., 1999; Von Kriegstein 
et al., 1999; Hartig et al., 2003; Nagy et al., 2004; Studer et al., 2006; Bouchard et al., 
2007; Persson et al., 2010), respectively. Abbreviations: ABHD6, serine hydrolase α/β-
hydrolase domain 6; CB1R/CB2R, CB1 or CB2 cannabinoid receptor; DB, dot blot; 
DAGLα/β, sn-1-diacylglycerol lipase α/β; GFAP, glial fibrillary acidic protein; IBA-1, 
ionized Ca
2+
-binding adaptor molecule 1; IH, immunohistochemistry; MAP2, microtubule-
associated protein 2; MGL, monoacylglycerol lipase; PHF, paired helical filament; PSD95, 
postsynaptic density protein 95; SNAP25, synaptosomal-associated protein of 25 kDa; 
VGLUT1, vesicular glutamate transporter 1; WB, Western blotting. 
Fig. S1 Aβ load, and biochemical indices of pre- and postsynaptic deficit in Alzheimer’s 
tissues. (A) Detergent-insoluble Aβ concentrations in hippocampal tissues as determined 
by ELISA. Data were expressed as pg of full-length Aβ(1-42) per µg protein. (B) β-Actin 
was used as loading control throughout. (B1) Although β-actin concentrations exhibited 
individual variations, these did not correlate with post-mortem delay. (C) AD is 
characterized by a progressive decrease in synaptosomal-associated protein of 25 kDa 
(SNAP25), a presynaptic marker of glutamatergic terminals in human brain (Garbelli et 
al., 2008). (D) Coincident reduction in postsynaptic density protein 95 (PSD95) (Von 
Kriegstein et al., 1999) levels indicates a loss of glutamatergic postsynapses in AD. 
SNAP25 and CB1R loads did not correlate across either the entire cohort (E) or particular 
disease states (data not shown). *p < 0.05 (Student’s t-test). The colours of individual 
data points identify subject subsets and correspond to those in Table S1. Abbreviations: 
B2-4, Braak stage II-IV cohort; B6, Braak stage VI group. 
Fig. S2 Quality control of novel antibodies. The specificity of our antibodies raised against the 
full N-terminus of the CB1R (in rabbit, A1), the AA205-287 fragment of DAGLβ (in rabbit, 
A2), AA790-908 of DAGLα (in guinea pig, A2), AA104-141 sequence of ABHD6 (in rabbit, 
A3), NAPE-PLD (41 AAs in its N terminus, in rabbit; A4) and AA171-206 of MGL (in rabbit, 
A5) have been tested by Western blotting. (A6) The specificity of our antibody raised 
against an internal epitope of MGL has been further validated in fetal MGL
-/-
 mice (MGL 
KO, embryonic day 16) by the lack of specific immunoreactivity in axons (arrows) 
populating the intermediate zone (IZ) of the cerebral cortex (Wu et al., 2010). β-III-tubulin 
was used as histochemical control, as well as a neuromorphological marker to delineate 
specific brain regions. Abbreviation: CP, cortical plate. Scale bars = 40 µm. 
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Fig. S3 Comparative analysis of the emission spectra of carbocyanine fluorophores after 
histochemical manipulations to human brain tissues. (A) Tissue autofluorescence in 
aged human hippocampus upon excitation by 488 (Cy2), 543 (Cy3) and 633 nm (Cy5) 
lasers. The glass-mounted section was not exposed to either primary or secondary 
antibodies. Emission spectra were presented as ‘Background’ in panels (C1) – (C3). Note 
that tissue autofluorescence primarily interferes with Cy2 signals. (B) Consecutive section 
exposed to Sudan Black-B but not to primary or secondary antibodies. Note that Sudan 
Black-B effectively reduces tissue autofluorescence at all three excitation wavelengths 
used. Emission spectra are shown as ‘Sudan Black’ in panels (C1) – (C3). Simultaneous 
immunofluorescence detection of Cy2 (DAGLα), Cy3 (DAGLβ) and Cy5 (MAP2) signals 
on Sudan Black-B-treated tissue background. Sharp emission peaks at expected 
wavelengths (‘Cy2/Cy3/Cy5’) with robust gain in signal intensity relative to Sudan Black-
B-stained tissues demonstrate the specificity of our histochemical techniques. 
Fig. S4 Post-mortem delay does not affect the levels of synaptic and 2-AG signalling-
related proteins. AEA and 2-AG levels rapidly change after death: post-mortem delay 
longer than 1h increases AEA concentrations. In contrast, 2-AG concentrations rapidly 
decline (within the first hour) after death (Palkovits et al., 2008). We therefore sought to 
determine whether post-mortem delay affects enzyme and receptor components of 2-AG 
signalling. Correlation analysis failed to establish a significant effect of post-mortem delay 
on protein levels from total brain homogenates (n.s.; non-significant) in our overall subject 
cohort as well as sample subsets (data for the latter not shown) when analyzing 
synaptosomal-associated protein of 25 kDa (SNAP25; A), postsynaptic density protein 95 
(PSD95; B), CB1 cannabinoid receptor (CB1R, C), sn-1-diacylglycerol lipase α (DAGL α ; 
D) and β (DAGLβ; D1), and serine hydrolase α/β-hydrolase domain 6 (ABHD6) 
concentrations. 
Fig. S5 Alzheimer’s disease affects the expression of neither the metabolic enzymes 
implicated in regulating anandamide (AEA) availability nor transient receptor 
potential V1 (TRPV1) channels. (A) Representative Western samples of fatty-acid amide 
hydrolase (FAAH) and N-acyl phosphatidylethanolamine-specific phospholipase D 
(NAPE-PLD) from control, moderate AD (B2-4) and severe AD (B6) cases. Neither AD 
progression (B) nor post-mortem delay impacts FAAH protein levels. Note the relative 
increase in severe AD (B6) that corroborates previous data on FAAH overexpression by 
plaque-associated microglia (Benito et al., 2003). (C,C1) Similarly, NAPE-PLD levels 
remain stable in AD. (D-D2) Cortical as well as hippocampal pyramidal cells (arrows) 
exhibit TRPV1-like immunoreactivity in human brain. Open rectangle identifies the position 
of (E-E2). TRPV1-like immunoreactivity decorates a subset of pyramidal cell dendrites in 
human brain, and appears as intermittent clusters of immunoreactive puncta (arrows). 
Open arrowheads point to a TRPV1
-
 dendrite. (F) Representative image of TRVP1 dot-
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blot signal. β-Actin was used as loading control. (F1) TRPV1 levels undergo an 
incremental – albeit non-significant – increase in B2-4 and B6 disease. (F2) Post-mortem 
delay does not affect TRPV1 concentrations. (G) [
3
H]resiniferatoxin ([
3
H]RTX) binding in 
total brain membranes of TRPV1
-/-
 and wild-type C57Bl/6 mice. (G1) The saturation curve 
in red represents ‘optimal’ saturation depicting the difference in specific binding (Bmax: 
130.2 ± 33.0 fmol/mg protein; Kd: 559 ± 94 pM) between WT and TRPV1
-/-
 mice in (G). 
(E)-capsaicin, a selective TRPV1 agonist (1 µM) failed to produce a displacement of 
similar amplitude (in blue; Bmax: 122.5 ± 10.6 fmol/mg protein; Kd: 1.26 ± 0.55 nM). This is 
partly due to (E)-capsaicin and its TRPV1-inactive enantiomer (Z)-capsaicin (1 µM) 
ligating the radioligand to the membranes in a non-specific manner. Accordingly, (E)-
capsaicin causes ‘negative’ displacement in the TRPV1
-/-
 (KO) mice and (Z)-capsaicin 
mimics this in WTs. This we took into account when calculating specific binding in the 
human and rat samples shown in (G2). (G2) TRPV1 binding in post-mortem control and 
AD brains using a 1.5 nM final concentration of [
3
H]RTX. Rat striatal synaptosomes were 
used as positive control. We find a transient (non-significant) increase in TRPV1 binding in 
B2-4 brains. Overall, AD does not affect TRPV1 binding capacity of the human 
hippocampus. 
Fig. S6 Analysis settings to minimize bias in data sampling for quantitative 
immunofluorescence. (A) Relative area coverage of CB1R
+
 and synaptophysin
+
 
structures over pyramidal cell dendrites in the stratum radiatum. (A1) Co-localization 
coefficients for CB1R and synaptophysin immunoreactivities. (A2) Pearson’s correlation 
coefficient of CB1R and synaptophysin fluorescence intensities is approximately 0, 
suggesting a lack of regulatory interplay in the two proteins. (A3-C) Fluorescence intensity 
profiles of markers analyzed by quantitative sampling procedures. Continuous lines 
represent population means, whereas dashed lines indicate population minima and 
maxima. Note that imaging settings were rigorously adjusted to eliminate bias through 
variable sampling. These data cumulatively support that quantitative data in this report 
represent the result of balanced sampling of aged control and/or AD tissues. 
Fig. S7 Image surveys of human hippocampi stained for CB1R or DAGLα/DAGLβ. (A-A2) 
Control hippocampus triple-stained for MAP2, a dendritic marker (A), CB1Rs (A1), and 
synaptophysin, a presynaptic marker (A2). (B-B2) Similar histochemical arrangements 
made to coincidently localize MAP2 (B), DAGLα (B1), and DAGLβ (B2). Dashed lines 
encircle anatomically distinct hippocampal subfields. Abbreviations: CA1-CA4, Ammon’s 
horn first-fourth subfields; GL, stratum granulare; mol, stratum moleculare; or, stratum 
oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars = 500 µm. 
Fig. S8 MGL protein content, URB602 and URB597 effects in Alzheimer’s vs. control 
frontal cortices used in biochemical assays. Note the significant decrease in both 
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soluble (A) and membrane-associated MGL (A1) in AD. Numbers correspond to 
independent samples per each subject group. (A2) Means ± s.e.m. (n = 9) of integrated, 
grey-scaled optical densities from experiments in (A,A1). (B) Membrane-associated MGL 
activity accounts for ~60% of total 2-AG hydrolysis activity as confirmed by URB602 
(King et al., 2007) application in membrane samples prepared from control human 
specimens. Note that URB602-sensitive 2-AG degrading activities are selectively lost in 
AD. (B1) 2-AG hydrolysis activity significantly increases in cytosol fractions from AD 
brains, as compared to controls. URB602 partially reduces 2-AG degradation in cytosolic 
fractions prepared from control brains and eliminates disease-associated enhancement 
of 2-AG catabolism in AD brains. (C) We also assessed the rate of AEA degradation in 
the same control and AD samples. Unlike MGL, FAAH protein levels did not change in 
the sample cohort (data not shown). Membrane-associated AEA hydrolysis significantly 
decreased, as compared to controls. Cytosolic FAAH activity was negligible (data not 
shown). URB597 eliminated ~ 63% of AEA hydrolysis activity in controls. Similarly, 
URB597 decreased AEA degradation by 51% in AD, confirming the contribution of 
FAAH. These data show that FAAH enzymatic activity is decreased in AD. ***p < 0.001, 
**p < 0.01 vs. controls; 
#
p < 0.05, 
##
 p < 0.01 vs. non-treated samples. Abbreviations: 
N.T., non-treated. 
Fig. S9 Molecular components of 2-AG signalling in APdE9 mice. We have explored whether 
APdE9 mice present phenotypic changes in 2-AG signalling, paralleling the 
neurochemical changes found in post-mortem human brains. (A) Comparison of protein 
expression profiles in wild-type mice (n = 2/group are shown) at 7 months (7 m) and 14 
months (14 m) of age. Expression profiling of excitatory synapse markers (SNAP25, 
vesicular glutamate transporter 1 (VGLUT1), and postsynaptic density protein 95 
(PSD95)) and 2-AG signalling network components at 7 months (A1) or 14 months of age 
(A2) reveals significant aging effects, but limited transgene contribution. (B-G) 
Quantitative analysis of SNAP25 (B; p < 0.05 vs. wild-type), VGLUT1 (C; p < 0.05; 7 vs. 
14 months for both genotypes), PSD95 (D; p < 0.05 vs. wild-type), CB1R (E; p < 0.05 vs. 
wild-type), DAGLα (F; p < 0.05; 7 vs. 14 months for wild-type control) and MGL (G) 
reveals age-independent SNAP25 upregulation, age- but not genotype-related loss of 
VGLUT1 (C), DAGLα (F) and MGL (G) expressions, and stochastic PSD95 (D) and CB1R 
(E) increases in APdE9 mice, as compared to wild-type littermates. Total MGL levels 
remained unchanged throughout the age-range analyzed. (H1-H3) Linear regression 
analysis of select neurochemical targets identifies a close, genotype-specific relationship 
between SNAP25 levels, possibly representing ectopic glutamatergic axonal sprouting 
around Aβ plaques (Bell et al., 2003; Hu et al., 2003), and CB1R (H1), DAGLα (H2) or 
MGL (H3) contents in APdE9 mice. Linear regression plots overall (all animals), in APdE9 
and wild-type subgroups are represented by dotted, dashed/dotted and dashed lines, 
respectively. Data were normalized to β-III-tubulin loading controls. These data, and 
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unchanged 2-AG concentrations in the cerebral cortex of APdE9 transgenic mice at 12 
months of age (H. Tanila, unpublished information), cumulatively suggest that APdE9 
transgenics might be inappropriate to recapitulate molecular underpinnings of disrupted 
2-AG signalling in AD. Data were expressed as mean ± s.e.m. 
Fig. S10 Depolarization-induced suppression of inhibition (DSI) under control recording 
conditions. (A) A brief (1s) depolarization step to 0 mV in CA1 pyramidal cells invariably 
induces significant DSI. (A1) AM251 occluded DSI in all neurons tested. (A) and (A1) are 
representative example traces. Cumulative data are referred to in Fig. 8C. 
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